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ASSESSING PATIENT SATISFACTION LEVELS FOLLOWING 
ENDOMETRIAL ABLATIONS IN THE TREATMENT OF ABNORMAL 
UTERINE BLEEDING TO DETERMINE EFFECTIVENESS  
 
SONIA GONZALEZ 
ABSTRACT 
Objective: The objective of this study was to evaluate outcomes for women following 
endometrial ablations due to abnormal uterine bleeding (AUB). These outcomes included 
patient-reported quality of life, satisfaction with the procedure, and treatment failure. 
Women experiencing heavy/regular bleeding were compared with women experiencing 
heavy/irregular bleeding.  
Design: The study was designed as a prospective cohort study of women aged 18-55 
years presenting to Women and Infants Hospital (WIH) in Providence, Rhode Island, for 
endometrial ablations due to AUB. Sixty-three participants in the study completed the 
Baseline Health Form, the Short Form-36 Health Survey (SF-36), and the Menstrual 
Bleeding Questionnaire (MBQ) upon enrollment. At the 3-month, 6-month, and 1-year 
follow-ups participants completed the SF-36 and the MBQ.    
Results: Baseline responses from the participants who were undergoing endometrial 
ablation found that 95.2% of women (n = 60) identified their periods as being heavy. 
From the total participants, 60.3% of women (n = 38) indicated their periods as being 
irregular. The SF-36 total score results demonstrate women with heavy/irregular bleeding 
		 vi 
experienced a greater negative impact in their quality of life. When broken down to the 
physical component score (PCS) and the mental component score (MCS) this difference, 
between women with heavy/regular bleeding and women with heavy/irregular bleeding, 
was minimized. Results from the MBQ revealed that women with heavy/irregular 
menstrual bleeding experienced a greater negative impact on their quality of life 
compared with women with heavy/regular bleeding. 
Discussion: Heavy bleeding is one of the defining factors in determining whether women 
seek further treatment for their menstrual bleeding, and when they do, they will usually 
attempt other therapies before pursuing surgery. The MBQ revealed a difference in 
quality of life between women with heavy/irregular bleeding and women with 
heavy/regular bleeding because this questionnaire measures bleeding and its impact on a 
woman’s life. The SF-36 total scores also showed a difference between heavy/irregular 
bleeding and heavy/regular bleeding. Breaking down the total SF-36 total score into the 
PCS and MCS minimized this difference. This questionnaire focused more on overall 
general health rather than bleeding and this focus may account for the smaller scoring 
differences among bleeding patterns. 
Conclusion: Similar proportions of women experiencing heavy/regular and 
heavy/irregular bleeding pursue endometrial ablations as a treatment for AUB. The SF-36 
demonstrated a greater burden on women’s general health when they have 
heavy/irregular bleeding. The MBQ provides a better measure to compare both bleeding 
patterns, aspects of bleeding, and demonstrates a more negative impact on quality of life 
for women with heavy/irregular bleeding.   
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INTRODUCTION 
  The goal of this project is to determine the effectiveness of endometrial ablations 
as a treatment for abnormal uterine bleeding (AUB) by conducting a prospective cohort 
study in which participants’ quality of life and menstrual bleeding are measured prior to 
the surgical intervention and at the 3-month, 6-month, and 1-year follow-ups. One of the 
most important factors in this study is to observe a difference and to compare these 
measures between women with heavy/irregular bleeding and women with heavy/regular 
bleeding. Participants self-report satisfaction levels pertaining to general health-related 
quality of life and bleeding-related quality of life. These data are used to determine the 
effect treatment has on women’s quality of life and satisfaction. The study looks to 
highlight the patient experience as an outcome and use it as a measure of success or 
failure of endometrial ablation. Overall, the hope is to capture a comprehensive picture of 
a woman’s experience with bleeding before and after treatment to evaluate how effective 
endometrial ablation is as an AUB treatment and to compare the experience of women 
with heavy/regular bleeding and heavy/irregular bleeding. 
 
The Need for Improved Treatment of Abnormal Uterine Bleeding 
 A large number of women seek treatment for menstrual disorders during their 
reproductive years, and this includes AUB and heavy menstrual bleeding (HMB) (1). 
Most studies have been retrospective in nature and tend to use objective measures when 
evaluating the success of a treatment for AUB. Often the objective measure is menstrual 
blood loss (MBL) from sanitary products (1). When treating and evaluating AUB in the 
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clinical setting, much of it is dependent on the patient’s assessment of blood loss and its 
effect on her quality of life (1). This highlights the subjective nature of AUB, especially 
when women are seeking treatment for the associated symptoms. As a result, patient 
experience as an outcome has become an important factor that should be measured (1). 
Women are often seeking treatment for menstrual disorders without clinically fitting the 
definition of AUB or HMB. This is one of the main reasons that it is critical to evaluate 
and compare women who present with heavy/regular and heavy/irregular bleeding. While 
bleeding is a cause for seeking treatment, its effect on quality of life, level of pain, and 
timing of menstrual flow are all contributing factors.  
 Currently there is no standard of care for evaluating patient-based outcome 
measures (PBOM) (1). Although available PBOMs vary in their quality, they are an 
essential tool when measuring clinical outcomes because they allow for the assessment of 
health and illness from the patient’s point of view (1). One of the most common 
questionnaires used in previous studies, the Short Form-36 Health Survey (SF-36), is a 
health-related quality of life (HRQOL) tool (1). Unfortunately, this type of questionnaire 
focuses on the participant’s physical and mental health in relation to their effect on day-
to-day activities (1). While these are important data measures, the SF-36 fails to take into 
account the other factors that lead many women with AUB to seek treatment.   
 What is missing in the overall picture is a more detailed look at bleeding quality 
of life (QOL) factors. This includes how bleeding or anxiety related to bleeding affect 
day-to-day activities (2). By measuring these factors before and after surgery, one can 
determine if the patient-reported outcomes for bleeding improve or stay the same. Often, 
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women who have endometrial ablations require further treatment. Having insight into 
how individual women respond to treatment post-surgery may help identify factors that 
not only motivate women to seek alternative therapies, including hysterectomy, but also 
contribute to what qualifies as a failed treatment.   
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SPECIFIC AIMS 
To determine the effectiveness of endometrial ablations in women suffering with AUB, 
the following aims are addressed: 
Aim 1. To compare patient satisfaction levels and quality of life measures prior to 
endometrial ablation and at 3-month, 6-month, and 1-year post-surgery follow-ups 
between women with heavy/regular bleeding and heavy/irregular bleeding. 
Aim 2. To compare health-related quality of life measures between women with 
heavy/regular bleeding and heavy/irregular bleeding through the SF-36 to evaluate 
general physical and mental health from the patient’s perspective. 
Aim 3. To compare bleeding quality of life measures between women with heavy/regular 
bleeding and heavy/irregular bleeding through the Menstrual Bleeding Questionnaire 
(MBQ), a disease-specific questionnaire, to evaluate changes in bleeding, flow, and 
timing. 
Aim 4. To determine whether certain factors influence women with heavy/regular 
bleeding and women with heavy/irregular bleeding to seek endometrial ablation 
treatment. 
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BACKGROUND AND SIGNIFICANCE 
Abnormal Uterine Bleeding 
One of the most common gynecological symptoms for which women seek 
treatment is abnormal uterine bleeding (AUB). This common women’s health problem 
not only affects them physically but places significant social and psychological burdens 
on the patient. During the reproductive years, AUB is usually characterized by any 
change in menstrual blood flow duration, volume, and pattern (3). There are several 
causes for the presence of AUB, and the condition may be due to one or several 
coexisting factors. AUB usually exhibits symptoms such as HMB, dysmenorrhea, and/or 
intermittent bleeding (4).   
Clinically, HMB is defined by at least a MBL of 80 mL or greater a cycle, but of 
the women seeking treatment for AUB, less than one-half present with HMB (1). This 
fact highlights that there are other factors which have to be considered to explain why 
women are seeking treatment for AUB. The tolerance level of individual women is 
variable, even when presenting with the same symptoms.  
AUB has an adverse effect on women’s lives, and the goal is to provide the most 
appropriate and effective treatment so that the patient is satisfied with the outcome. 
Although many types of treatments exist, ranging from pharmacologic agents to surgery, 
the effectiveness of treatment varies, and so does the associated risk. In all cases, several 
factors should be taken into account when deciding on a course of treatment. These 
factors include what the patient’s preferred outcome is and what results the current 
treatments actually deliver.  
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FIGO-Classification System (PALM-COEIN) 
In 2011, the International Federation of Gynecology and Obstetrics (FIGO) 
created a universal nomenclature and classification system for the causes of AUB. This 
system differentiates between chronic AUB and acute AUB. Chronic AUB is defined as 
being present for at least the past 6 months and constitutes bleeding from the uterine 
corpus which is irregular in volume, duration, and regularity but does not require 
immediate treatment (5). Acute AUB is characterized as a heavy bleeding episode which 
requires immediate treatment to prevent further blood loss (5).  
The FIGO AUB classification system termed PALM-COEIN, is a solution to the 
inconsistent nomenclature used to describe AUB as well as its multitude of causes (5). 
PALM-COEIN works to classify the etiology of AUB. Importantly, the system 
recognizes that AUB can be caused by a variety of factors, some of which may be 
asymptomatic, such as adenomyosis, leiomyomas, and polyps (5). If the classification 
system is broken down, it is significant to note that the PALM group refers to structural 
anomalies which can be measured and visualized either through histopathology or 
imaging techniques (5). The COEIN group refers to causes of AUB that are due to non-
structural anomalies which cannot be measured or visualized (5).  
PALM Group 
Within the PALM group of the FIGO AUB classification system, each letter 
denotes a structural anomaly that causes AUB. PALM stands for polyp, adenomyosis, 
leiomyoma, and malignancy and hyperplasia. Polyps are epithelial proliferations found 
on the endometrium or cervix, and although often asymptomatic, they are thought to be a 
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cause of AUB (5). The link between adenomyosis and development of AUB is harder to 
pinpoint as a result of inconsistencies in histopathological criteria and because most cases 
are diagnosed by testing the specimen after hysterectomy (5). Despite these issues, 
adenomyosis can be diagnosed by sonogram or magnetic resonance imaging (MRI). In 
both cases, the presence of endometrium within the myometrium is indicative of 
adenomyosis (5). Leiomyomas, also known as myomas or fibroids, are benign 
fibromuscular tumors found within the myometrium, and they tend to be asymptomatic 
(5). The benign tumors are often not thought to be the cause of AUB, but there is a 
secondary classification system that categorizes them based on whether they are 
submucosal or other. A leiomyoma classified as submucosal is found within the 
endometrial cavity, and it is these lesions which are thought to play a role in AUB 
genesis (5). Finally, malignancy and hyperplasia could be causes of or just associated 
with AUB. In these cases, further classification is required through either the World 
Health Organization (WHO) or FIGO systems (5). 
COEIN Group 
 Within the COEIN group of the FIGO AUB classification system, each letter 
denotes a non-structural anomaly that causes AUB. COEIN stands for coagulopathy, 
ovulatory dysfunction, endometrial, iatrogenic, and not otherwise classified. 
Coagulopathy refers to disorders of hemostasis which have been found to be present in 
13% of women suffering from HMB (5). It remains unclear how much these disorders 
contribute to or are the cause of AUB, but disorders of hemostasis should not be 
discounted (5). Ovulatory dysfunction is a known cause of AUB genesis and manifests as 
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unpredictable timing and variable menstrual flow, sometimes resulting in HMB (5). The 
etiology of ovulatory disorders remains elusive, but they can be linked to 
endocrinopathies, such as polycystic ovary syndrome, hypothyroidism, obesity, or 
anorexia (5). Endometrial causes of AUB occur in the presence of predictable and cyclic 
menstruation. During HMB, there may be present a disorder that deregulates the 
mechanism of endometrial hemostasis (5). When AUB is classified as iatrogenic, it is 
thought to be caused by medical interventions or devices. Medicated or inert intrauterine 
devices and pharmacologic agents are AUB contributors. These interventions impact the 
endometrium, coagulation mechanisms, or ovulation (5).  
Quality of Life 
 Although many current studies of AUB and HMB use blood loss as a measure 
when evaluating women, this assessment only provides one source of data and does not 
truly reflect the experience of the women suffering from the adverse effects of AUB and 
HMB. One of the key factors influencing women’s quality of life is the inability to 
control menstrual flow (2). Women tend to worry about bleeding through their clothes, 
which leads to changes in plans or missed work (2). Certain statistics estimate that 
women who suffer with AUB work four fewer weeks each year than women who do not 
have AUB (6). This fact highlights the burden that AUB places on women to the point 
where they have to rearrange their lives to accommodate associated symptoms.  
 The goal of treating AUB should be to alleviate symptoms for the women and to 
improve their quality of life. With this aim in mind, it is important to recognize that 
tolerance levels for symptoms and quality of life are subjective measures, varying from 
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woman to woman. Different past studies have tried to evaluate patient outcomes after a 
procedure, but the number of possible outcomes, along with the various interventions 
available, makes comparisons among studies difficult (7). In order to better evaluate the 
outcomes of women, a standardized patient-based outcome measure would be beneficial.  
 The effect of AUB on a woman’s life is best highlighted by the fact that about less 
than one-half of the women seeking treatment actually qualify as having HMB, which is 
a MBL of greater than 80 mL (1). Furthermore, one-half of these women seek treatment 
for a MBL of less than 40 mL, which is indicative that quality of life disruption is not 
solely reliant on the level of MBL (1). In other words, there are additional factors that are 
motivating women to seek treatment. HMB manifests as a variety of symptoms, and what 
is acceptable for one woman may be problematic for another (2). For women seeking 
treatment for AUB, most of them are looking for a reduction in the amount of bleeding to 
a point that is acceptable to them (3). Although patients may be satisfied with the AUB 
treatment they receive, any correlation with menstrual bleeding satisfaction remains 
unclear (3). For some women, the unalleviated bleeding symptoms of AUB persist after 
treatment and often serve as an impetus to seek further treatment. In some cases, 
menstrual bleeding outcome is satisfactory to the patient, but other symptoms persist 
which remain problematic, such as pelvic pain, and thus the patient seeks further 
treatment (8). Ultimately, the success of a treatment in improving a woman’s symptoms 
and quality of life is subjective and based on how satisfied she is with the treatment 
outcome and her own inclination to continue with the current plan of therapy (9). 
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Current Treatments 
 There are currently a wide range of treatments available for AUB. Typically, 
medical treatments are considered first-line therapies, and many women choose to pursue 
this route of treatment prior to any type of surgical treatment. The efficacy of medical 
therapies is variable, and often, MBL is only reduced by about 50% (10). However, the 
levonorgestrel-intrauterine system (LNG-IUS) has shown more promise as a medical 
therapy, with HMB being reduced by almost 94% at three months (10). If women pursue 
surgical treatment, options include endometrial ablation or hysterectomy. Hysterectomy 
results in a 100% reduction of HMB, but this treatment is more invasive and carries more 
risk. By contrast endometrial ablations are less invasive and pose less risk. Ultimately, 
the best treatment choice is dependent on the patient’s desired outcome of either a 
reduction or disappearance of symptoms. 
Medical 
 Medical treatments are often the first-line therapy for AUB, and options can be 
either hormonal or non-hormonal. Although medical treatment can reduce MBL, they are 
associated with high rates of non-compliance (11). Such medical treatments include the 
LNG-IUS, antifibrinolytic drugs, nonsteroidal anti-inflammatory drugs (NSAIDs), 
progestogens, combined hormonal contraceptives, danazol, and a combination of drugs 
(12). Each of these medications varies in the mode of action and the ability to treat AUB. 
 Non-hormonal treatments include NSAIDs and antifibrinolytics. Women who 
present with HMB have been found to exhibit elevated levels of prostaglandins within the 
uterine tissue (12). NSAIDs work by inhibiting cyclooxygenase, an enzyme which is 
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responsible for converting arachidonic acid to prostaglandins (12). Some of the most 
common NSAIDs used are mefenamic acid and naproxen. These drugs can reduce blood 
loss from about 33% to 55% while simultaneously alleviating menstrual cramps (9). 
Typically, NSAIDs are taken during menstruation and exhibit side effects like headaches 
and gastrointestinal disturbances (9). It has also been shown that women with HMB tend 
to have higher endometrial levels of plasminogen activators, which are responsible for 
enzymes that cause fibrinolysis, or blood clot degradation (12). By inhibiting this 
process, antifibrinolytic drugs can reduce bleeding from about  40% to 50% (9). Taken 
only during menstruation, antifibrinolytics have side effects that can include nausea and 
diarrhea (9).   
 Other drugs typically used are hormonal in nature, and they work to regulate the 
menstrual cycle and prevent unscheduled bleeding and HMB (12). Progestogens are 
hormones which function to suppress endometrial growth and activity and eventually 
lead to endometrial atrophy (12). Although progestogens are not considered the best 
treatment for long-term use because of their side effects of bloating, breast tenderness, 
and headaches, they do alleviate heavy bleeding (9). Women who take combined 
hormonal contraceptives typically experience from 40% to 50% reduction in blood loss 
(12). These contraceptives include the oral contraceptive pill, the contraceptive patch, or 
the vaginal ring. They work to suppress ovulation and inhibit endometrium growth (12). 
When used continuously, they can reduce heavy bleeding and may even reduce the 
number of bleeding episodes in a year (11). Side effects of this treatment may include 
irregular bleeding, nausea, breast tenderness, weight gain, and an increased risk of arterial 
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thrombotic events and venous thromboembolism (9). Danazol, a synthetic hormone, 
works by shrinking the endometrium, effectively leading to reduced blood loss, but is 
only rarely used because of its androgenic side effects (9).  
One of the most successful medical treatments is the LNG-IUS. Typically 
implanted within the uterus, the device releases the progestogenic hormone, 
levonorgestrel, to suppress endometrial activity while also acting as a contraceptive (9). 
This leads to endometrial atrophy and decreased uterine vascular density, which 
ultimately leads to reduced and controlled bleeding (12). Studies have found that of the 
women who choose LNG-IUS, 86% see a reduction at three months, and at one year 97% 
see a reduction (12). Evidence suggests that AUB caused by AUB-C (AUB-
coagulopathy), AUB-E (AUB-endometrial dysfunction), AUB-O (AUB-ovulatory 
dysfunction), and AUB-N (AUB-not otherwise classified) can benefit greatly from this 
treatment in regards to effectiveness and safety (11). Compared to other medical 
treatments for AUB, LNG-IUS is superior and has resulted in comparable quality of life 
improvements when compared to surgical procedures (12).  
Surgical 
 Two of the most common surgical treatments for AUB are hysterectomy and 
endometrial ablation. Hysterectomy has long been regarded as the definitive treatment of 
HMB because it leads to amenorrhea and high patient satisfaction levels. About one-half 
of all hysterectomies worldwide are to treat HMB (10). Despite its high level of success, 
hysterectomy does carry increased risk. Surgery can be done abdominally, vaginally, or 
laparoscopically, but evidence suggests that the vaginal surgery leads to shorter recovery 
	13 
time and less complications (9). No matter what route is pursued, hysterectomy remains a 
high-risk procedure and can lead to hemorrhage, infection, and wound-healing problems, 
accompanied by a lengthy recovery period after surgery (9). Nevertheless, hysterectomy 
has a 100% success rate, and three years after surgery women report a 95% level of 
satisfaction (9). 
 As a result of the risk that accompanies a hysterectomy and surgical recovery time 
needed, women may opt for endometrial ablations. First- and second-generation 
techniques exist for endometrial ablations, with the newer techniques providing reduced 
recovery time, less risk, and faster procedures. Both techniques destroy the endometrium 
and have been shown to have similar success rates and complication profiles (9). Patients 
reported satisfaction levels greater than 90% with endometrial ablations, but 30% of these 
patients seek further treatment, opting for a hysterectomy within four years (12). As 
endometrial ablations are less invasive, so patients may choose this procedure before 
pursuing a hysterectomy.  
 
Endometrial Ablations 
 Because endometrial ablations are less invasive when compared with 
hysterectomy, they have become a viable alternative for treatment of AUB. This is an 
important factor for women suffering with HMB for whom medical treatment has not 
worked and they seek a less invasive procedure which allows for the preservation of the 
uterus (9). This surgical procedure is recommended for women who are pre-menopausal, 
have finished child-bearing, and do not have endometrial cancer, and/or hyperplasia (13).  
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  An endometrial ablation involves the destruction of the endometrium, superficial 
myometrium, and underlying basal glands (9,10). It is believed that the powerful 
regeneration of the endometrium is due to the presence of these basal glands, and their 
removal aids in suppression of menstruation (10). Performing the procedure when the 
endometrium is thin or atrophic leads to increased effectiveness of endometrial ablations, 
and this conditions can be achieved in three ways (13). The first method schedules the 
procedure when the endometrium is less than 4mm in thickness, usually in the immediate 
post-menstrual phase (13). The second method uses dilation and curettage (D&C), to 
basically removes extra tissue from the endometrium (13). The third method is hormonal 
in nature, and involves the use of gonadotropin-releasing hormone (GnRH) analogs, 
danazol, and/or progestogens. Systematic reviews of these hormonal therapies have found 
that use of GnRH analogs tend to be more successful and lead to higher rates of 
amenorrhea post-surgery (13).  
Types of Endometrial Ablations 
 Because of the less invasive nature of endometrial ablations, their popularity as an 
alternative therapy for AUB has increased over the last two decades (10). No matter what 
ablation procedure is performed, the goal is to destroy the endometrium. Endometrial 
ablations can be broken down into two groups: first- and second-generation techniques.  
First-generation techniques refer to hysteroscopic procedures that require the use 
of a hysteroscope to directly visualize the uterus (10). Such procedures include ablation 
with either laser, radiofrequency, or electrical energy, and endometrial resection (13).  
Success of these procedures is dependent on surgical skill, training, and technique (9,10). 
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Furthermore, first-generation techniques require an operating room, the administration of 
general or regional anesthetic, and a short hospital stay (9).   
Second-generation techniques do not always require direct visualization of the 
uterus and can be non-hysteroscopic. Furthermore, these techniques are often called 
‘global’ techniques because they focus on treating the whole endometrial cavity (14).  
Therapies include cryoablation, hot saline solution irrigation, laser hyperthermy, 
microwave ablation, photodynamic therapy, and the heated balloon system (10). Other 
second-generation techniques do use a hysteroscope for surgery and they are 
hydrothermal ablation and endometrial laser intrauterine thermal therapy (10). Studies 
that have carried out direct comparisons of the procedures have found that bipolar 
radiofrequency and microwave ablation have been the most successful in producing 
amenorrhea (14). Newer techniques use more sophisticated equipment and are not as 
dependent on surgical skill for a successful outcome (9). They can be done with local 
anesthetic and are done as day or outpatient surgeries (9).  
When compared to first-generation techniques, second-generation techniques 
were found to have similar success rates and complication profiles, while also being more 
cost-effective (9). Women who underwent either first- or second-generation techniques 
experienced significant improved HRQOL (15). Despite this, there is some evidence that 
second-generation techniques may be more favorable in terms of success. Second-
generation techniques require less time and afford a quicker recovery to normal activities 
and return to work because of the lack of general anesthesia (16). In fact, when looking at 
women who proceeded to get a hysterectomy after trying out an endometrial ablation, 
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these women tended to have undergone first-generation techniques (16). Overall, the 
popularity of second-generation techniques has grown since their introduction and have 
slowly displaced first-generation techniques.  
Complications and Outcomes 
Although generally safer than hysterectomies, these first-generation endometrial 
ablations carry a small risk of hemorrhage, uterine perforation, fluid overload, and/or 
infection (9). Many women opt for an endometrial ablation because of its less invasive 
nature, but there is no guarantee that that it will alleviate bleeding symptoms to 
acceptable levels. One study found that further surgical treatment was required in 38% of 
cases (9). Complications from second-generation techniques include nausea, vomiting, 
uterine cramping, and pain (10). Even though women may require further treatment after 
a second-generation endometrial ablation, fewer women do so compared to a first 
generation procedure (30% requiring a hysterectomy after four years), fewer women do 
so compared with a first-generation procedure (16,17).  
Perforations of the uterine cavity have been raised as a risk, especially for first-
generation endometrial ablations. Although second-generation procedures carry a lower 
risk of this complication, it is possibly counteracted by fail-safe mechanisms found in the 
devices which shut down when incorrect positioning is detected (18).  
Pregnancy is another complication that, although not mentioned previously, is of 
concern. Hysterectomy prevents pregnancy by the removal of the reproductive organs, 
and the LNG-IUS acts as a contraceptive device by implanting in the uterus. An 
endometrial ablation removes the endometrium, which in itself reduces the possibility of 
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embryonic implantation but does not eliminate it (18). For this reason, women who 
choose this surgical treatment should have a contraception plan in place, which can 
include the LNG-IUS or combined hormonal contraceptives (18). Pregnancy occurs in 
about 0.7% of cases after endometrial ablation and is accompanied by complications such 
as spontaneous abortion, abnormal placentation, intrauterine growth restriction, and the 
premature rupture of membranes, (13,19). Furthermore, 42% of these women experience 
premature delivery, 71% require a caesarean section, and 13% result in perinatal 
mortality (18).  
  Another complication resulting from endometrial ablations in women with tubal 
ligations is post-ablation tubal sterilization syndrome (PATSS). Following the removal of 
the endometrium, necrosis and inflammation can result and lead to intrauterine adhesions 
and uterine contracture (19). Moreover, a cornual hematometra can result and lead to 
retrograde menstruation entering an obstructed fallopian tube (8,19). This ultimately 
leads to cyclic pain with or without menstruation (19). Often, the best way to diagnose 
PATSS is through an MRI, and treatment options include removal of the fallopian tube, 
salpingectomy, or hysterectomy (19).  
A final concern following endometrial ablations is that of endometrial 
malignancies. Usually women with a history of endometrial cancer or hyperplasia are 
advised to avoid this type of surgery (18). Typically, any malignancy should be ruled out 
by hysteroscopy or endometrial biopsy prior to the procedure (18). Although most 
second-generation techniques do not require visualization of the uterus or biopsy, one of 
the advantages of the first-generation transcervical resection technique was the collection 
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of a specimen for further evaluation (18). It is thought that during the ablation procedure, 
islands of viable endometrium may remain and serve as points for the development of 
endometrial cancer (13). Furthermore, factors present prior to the ablation procedure, 
such as obesity, polycystic ovary syndrome, and chronic AUB-O may cause long-term 
exposure to estrogen and increase the risk of endometrial hyperplasia and malignancy (8). 
 
Patient Satisfaction 
Satisfaction with Bleeding and Effect on Daily Activities 
The patient experience as an outcome has come to carry more weight, and patient 
satisfaction as it relates to bleeding is considered an important outcome (7). Furthermore, 
patient satisfaction is strongly linked to quality of life, and often this is not isolated to 
dissatisfaction with heavy bleeding, but irregularity of bleeding or the pain due to the 
passage of large clots (7,16). Bleeding that interferes with daily life can contribute to 
higher levels of dissatisfaction.    
 AUB places a burden on HRQOL measures which include areas related to sex, 
emotion, finance, and career (11). Women often report taking time out of work to manage 
their bleeding. This can amount to a few days each month around the time of 
menstruation, but over a year this can lead to an income loss of about $1692 (15). One 
study found that when bleeding was a problem, women tend to refer to the impact on 
their daily lives. This could manifest in not being able to fulfill domestic or workplace 
roles, always being in the vicinity of a restroom, or taking extra measures to not stain 
clothing and furniture (20). In terms of judging their own periods, women tend to be 
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unsure as to what constitutes a normal amount of bleeding, and oftentimes they classify 
their blood loss based on what they feel is normal from past experiences (20). Even when 
it came to classifying the most bothersome aspect of HMB, women ranked pain as their 
primary concern, followed by mood changes/tiredness, and heaviness (20).  
The importance of patient satisfaction and quality of life is best highlighted when 
women are initially seeking treatment. Based on population-based studies, about 10% of 
women seeking treatment could be objectively classified as presenting HMB (15). Yet 
when women self-reported this information, about 30% indicated they suffered from 
HMB (15). The discrepancy in the numbers reported has been seen in various studies and 
indicates that subjective measures may be better indicators of who will seek treatment 
and how satisfied they feel about their current bleeding situation. One of the biggest 
problems in evaluating patient satisfaction and quality of life is an understanding of the 
prevalence of AUB in the population. The reason being that diagnosis of AUB can be 
objective, and might underestimate the number of women with the condition because it 
relies on the physician to make the diagnosis, or it is subjective and dependent upon the 
patient to rate the severity of their symptoms (15). Overall, subjective measures are better 
at predicting who will seek out treatment for AUB (15). 
It has become more evident that AUB and HMB place a burden on women, 
because HRQOL is affected by efforts focused on managing bleeding, but also by the 
physiological effects that result from excessive blood loss such as fatigue and anemia 
(21). Past studies have placed an emphasis on MBL as an indicator of HMB, but this is 
not always the best method of assessing AUB in women. While MBL is an important 
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measure other factors exist that may have a bigger impact on women with AUB. In fact, 
qualitative research has shown that assessment of menstrual problems are best addressed 
by emphasizing its impact on daily life as opposed to MBL (20).   
When looking at satisfaction levels for the treatment of AUB, women experience 
higher levels when they undergo a hysterectomy as opposed to an endometrial ablation 
(16). Although satisfaction with treatment tends to be high overall for these procedures, 
hysterectomy tends to be the definitive treatment for AUB because it eliminates 
menstruation completely and pelvic pain (3). Before treatment women are managing their 
symptoms, but with a hysterectomy those symptoms are eliminated and thus the effect of 
bleeding on QOL is also eliminated. This is not always the case with an endometrial 
ablation, mainly because not all causes of AUB can be treated with this procedure. While 
some women may have a cessation of symptoms, other may see that their bleeding 
situation remains unchanged. The most important factor dictating treatment choice and 
outcome is the woman’s preference. In other words, if a woman prefers less invasive 
therapy she will opt for the endometrial ablation instead of the hysterectomy (15). And if 
that treatment can reduce bleeding symptoms to an acceptable level for the patient’s 
lifestyle, the patient is more likely to be satisfied (3).  
Lack of Standardization in Determining AUB Outcomes 
 Many studies have been conducted on AUB, but one of the problems lies in the 
fact that no real standard tool exists in evaluating symptoms, outcomes, and treatment. 
This makes comparisons across studies difficult to evaluate and makes it difficult to reach 
concrete overall conclusions. The need to standardize and validate outcomes is important 
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because studies may focus on patient satisfaction with treatment as opposed to 
satisfaction with menstrual bleeding (3). Furthermore, differences related to bleeding and 
QOL as opposed to MBL would be beneficial because they take into account the 
subjective nature of AUB (6). Currently there are a number of questionnaires and surveys 
that have been approved to evaluate AUB, but many times they measure different things. 
Until a consensus is reached, meaningful conclusions across studies will be difficult to 
attain. The questionnaires used in this study are the SF-36 and the MBQ.  
SF-36 
 Over the past few decades, there has been a growing consensus that the patient’s 
point of view is an important factor when it comes to evaluating a medical outcome. 
Evidence already exists that show objective measures are not always representative of a 
patient’s personal experience. The SF-36 was developed with not only this goal in mind, 
but also to assess eight different health concepts: physical functioning (PF), limitations in 
role physical (RP) activity, bodily pain (BP), general health (GH), vitality (VT), social 
functioning (SF), limitations in role emotional (RE) activity, and general mental health 
(MH) (22). These eight domains of the SF-36 were then grouped into either the physical 
component score (PCS), which consisted of the PF, RP, BP, and GH, or the mental 
component score (MCS), which consisted of VT, SF, RE, and MH (23). The combination 
of the PCS and MCS yielded the total SF-36 score for an individual. The survey was 
created to address general health concepts that were applicable to any group regardless of 
age, treatment, or disease. Despite this, there is some evidence that because the SF-36 
measures two different dimensions, the physical and the mental, that the PCS and MCS 
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are more valid than the combined total score (23). Although this evidence exists, the SF-
36 remains one of the more common questionnaires used in heavy bleeding studies. 
By creating a validated and standardized test, the idea is to establish a standard in 
which to compare what is being measured across different studies. One of the strengths of 
the SF-36 lies in that it can compare the burden of different diseases or treatments (22). 
This becomes especially important when comparing a disease to the general population 
(15). It is an easy survey to use because it is short, it provides depth and breadth of 
measurement, and there are various forms of administering the survey (22). While the 
SF-36 has been used when evaluating AUB outcomes among women, and has been 
deemed valid and reliable, women may encounter difficulty answering questions because 
AUB can be intermittent and symptoms are rarely life threatening (2). The SF-36 is a 
general health survey and fails to further delve into the specific problems surrounding 
bleeding.   
MBQ 
 Studies have found that when it comes to menstrual bleeding specific health 
problems, a specific QOL instrument would be more beneficial when evaluating AUB 
and HMB (2). At the moment though, there is no standard tool in use, which makes 
comparisons across studies difficult to evaluate. The MBQ has been validated and 
incorporates how bleeding and the anxiety of bleeding can affect quality of life when it 
comes to daily activities (2). Most importantly, the MBQ takes into account the 
subjective nature of AUB and HMB symptoms, and produces significant differences 
between women with no problem and women with heavy bleeding (2). Although heavy 
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bleeding is still impacted by a physical and mental aspect, the MBQ shines a light on 
social embarrassment. It highlights that social embarrassment is a big factor when it 
comes to heavy bleeding and the questionnaire approaches this aspect in a meaningful 
manner (2). It accurately summarizes women’s experience when done retrospectively and 
it measures different factors than the SF-36 (2). Until a definitive standard is developed 
or agreed upon, a disease-specific instrument accompanied by general health instrument 
could be beneficial.    
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CURRENT STUDIES 
 Endometrial ablation has been evaluated in randomized clinical trials for women 
with heavy and regular bleeding only. In clinical practice, many obstetricians, 
gynecologists and surgeons treat women with heavy/irregular bleeding with endometrial 
ablation. There is limited evidence on the safety and effectiveness of endometrial ablation 
in women with heavy/irregular bleeding patterns. Furthermore, studies evaluating patient 
characteristics that influence treatment effectiveness from the patient’s perspective are 
lacking in a prospective cohort study. Most studies have taken a retrospective approach 
when taking bleeding pattern into account and/or evaluating endometrial ablation failure 
(8,17). The importance of a prospective cohort study is that subjects’ data are captured 
prior to treatment, when more accurate accounts of current symptoms can be provided. 
Doing this minimizes recall bias and subjects can be followed up to provide an account of 
how satisfied they are with treatment and the impact it has had on their quality of life.  
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STUDY DESIGN AND METHODS 
Overview 
  A prospective cohort study was conducted on endometrial ablations performed at 
Women and Infants Hospital (WIH) in Providence, Rhode Island. A list of patients 
provided by the Director of Surgical Services or his appointee was provided a week in 
advance and reviewed for eligibility criteria. In total, there were 63 women surveyed who 
met the criteria, consented to be part of the study, filled out the Locator Form, and 
completed the questionnaires consisting of the Baseline Health Form, the Menstrual 
Bleeding Form (MBQ), and the Short Form-36 Health Survey (SF-36) version 2 (SF-
36v2).      
 This study aimed to determine whether or not pre-operative bleeding pattern had 
an impact on post-operative patient outcomes including satisfaction, quality of life, and 
treatment failure. This study aimed to capture crucial data in regards to these measures 
prior to treatment in the hopes of better evaluating and understanding changes in any of 
these factors. Data from participants was captured on the day of consent. Additional 
paperwork, including the Locator Form, the MBQ, and the SF-36, were completed again 
at 3, 6, and 12 months following the procedure. Initial contact was done in person, and 
subsequent surveys were filled out by mail. Follow-up questionnaires were sent out two 
weeks prior to the scheduled follow-up date, and participants could be contacted up to 
one month after this date. Study data were collected and managed using REDCap 
(Research Electronic Data Capture) electronic data capture tools hosted at Care New 
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England (24). REDCap was a password protected, web-based application designed for 
research study data capture. Data was recorded and de-identified within the database.    
 
Recruitment 
 Women who were recruited for the study were eligible if they presented at WIH 
surgical services for an endometrial ablation. Furthermore, women had to be between the 
age of 18 and 55 years of age, have the ability to read in English, and be able to give 
informed consent. Date of recruitment corresponded to the date on which they had the 
endometrial ablation was performed.  
 Potentially eligible patients were approached while waiting in the pre-operative 
area. The research assistant explained the study to the patient and proceeded to obtain 
informed consent (Appendix A) if the patient was interested, able to read English, and 
able to give informed consent. The patient was informed about what the study entailed 
and any questions or concerns they had surrounding their participation in the study were 
answered. Once consent was given, the participant was assigned a random study number 
for use in the database. The next step was to obtain detailed contact information from the 
patient for future communication by filling out the Locator Form (Appendix B). Once 
this was completed, the participant was given three questionnaires to fill out: the Baseline 
Health Form (Appendix C), the Short Form-36 Health Survey (SF-36) (Appendix D), and 
the Menstrual Bleeding Questionnaire (MBQ) (Appendix E). Upon completion of these 
forms, the health care provider performing the procedure was asked to answer question 
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23 of the Baseline Health Form for the patient’s pre-op diagnosis based on the FIGO 
PALM-COEIN classification system for AUB etiologies.  
 
Measures 
  The questionnaires used in this study were chosen because they had the potential 
to capture a complete picture of a participant’s quality of life and satisfaction with 
bleeding prior to surgery. Their use was consistent with the stated aims of the study.  
Baseline Health Form 
 The first questionnaire, the Baseline Health Form, was a 23-question form (see 
Appendix C). The questionnaire focused on obtaining a complete picture of a woman’s 
abnormal uterine bleeding and was broken down into sections on menstrual history, past 
treatments, obstetric history, gynecological and surgical history, demographic 
information, and the healthcare provider’s determination of the etiology of the abnormal 
uterine bleeding. Participants were informed that for this questionnaire, the term “period” 
referred to any bleeding from the vagina, even when that bleeding was irregular.  
 The Baseline Health Form was filled out one time by the participant in person on 
the day of consent prior to their surgery for endometrial ablation. The form asked for no 
identifying information from the participant. Of the questions in this survey, questions 1 
to 4 were important in classifying women as either having heavy/regular bleeding or 
heavy/irregular bleeding. Question 5 asked women who had heavy/regular bleeding or 
heavy/irregular bleeding if they had tried any treatments in the past two years. If they 
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answered “Yes,” they then proceeded to question 6 where they could check off the 
treatments they had undergone.  
 Questions 7 to 10 focused specifically on the women’s obstetric history, inquiring 
about how many times they had been pregnant, how many pregnancies resulted in a 
delivery, how many of those deliveries were caesarean sections, and if there had been any 
miscarriages, abortions, or ectopic pregnancies. Any of these questions resulting in a 
positive answer asked for the number of times each instance had occurred.  
 Questions 11 to 14 concentrated on the women’s gynecological and surgical 
history. Information was requested about whether they had ever been told by a healthcare 
provider that they had endometrial hyperplasia. Other questions asked about whether they 
ever had an endometrial biopsy (if so, when), D&C unrelated to a pregnancy (if so, 
when), an endometrial polyp (if so, when it was removed), and certain other 
gynecological surgical procedures performed.  
 Eight questions encompassed demographic information. Questions 15 and 16 
inquired about height and weight, respectively. Questions 17 and 18 asked about 
ethnicity, race, and most common language spoken at home. Question 20 inquired about 
their current marital status. Questions 21 and 22 asked about their employment situation 
and their highest level of education, respectively. The final question, question 23, was for 
their healthcare provider to designate the etiology of the participant’s AUB. 
SF-36 
 The second questionnaire, the SF-36, consisted of 11 questions concerning the 
patient’s general and mental health (Appendix D). These questions each belonged to one 
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of eight domains. Questions belonging to PF, RP, BP and GH made up the PCS. The 
questions belonging to VT, SF, RE and MH made up the MCS. The PCS and MCS were 
then combined to yield the total SF-36 score. 
Question 1 asked the patient to rate current health and question 2 had the 
participant compare current health to how it was one year ago. Question 3 asked the 
participant to rate how their current health impacted the ability to carry out a total of ten 
listed activities.  
 Question 4 asked the participant to think about the last four weeks and determine 
if physical health had impacted work or other daily activities. There were four 
subcategories to this question. Similarly, question 5 asked the participant if emotional 
problems impacted work or daily activities. There were three subcategories to this 
question. Questions 6 to 8 asked the participant to reflect on the past four weeks and rate 
how physical and emotional problems interfered with normal activities, how much bodily 
pain was present, and if the pain interfered with work. 
 Question 9 asked how the participant felt over the past four weeks. This question 
had nine subcategories. Question 10 asked how much physical and emotional problems 
interfered with social activities in the last month. Finally, question 11 asked the 
participant to rate how “True” or “False” four statements were in describing the 
individual. 
 Each of the questions answered in the SF-36 corresponded to a number value. 
Once the questionnaire is filled out, a numerical sum was tabulated, ranging from 0-100. 
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This overall sum gave the score of the SF-36, which indicated how general physical and 
mental health is impacting a participant’s overall quality of life and satisfaction levels.  
MBQ 
 The third questionnaire, the MBQ, was designed specifically to evaluate bleeding 
as related to quality of life and satisfaction levels (see Appendix E). The questionnaire 
consisted of a total of 21 questions, 20 of which were scored and an initial unnumbered 
question which asked if the participant experienced any bleeding in the past month. If the 
answer was “Yes,” then the participant continued on with question 1; but if the answer 
was “No,” then the individual skipped to question 12.  
 The MBQ score was broken down into four aspects: heaviness, quality of life, 
irregularity, and pain. Eight questions (1-7, 9) made up the heaviness section. These 
questions asked women to describe their period, the number of sanitary products they 
soaked, the use of an incontinence brief or high absorbency sanitary product, the number 
of episodes when bleeding soaked outer clothes, the number of times awoke during the 
night to change their sanitary products, the number of times they passed blood clots, and 
whether the clots stained their clothing, and the length of their period.  
 Eight questions (10-12, 14-18) made up the quality of life portion of the 
questionnaire. These questions asked women how many days their work suffered because 
of their bleeding, how many work days they missed, how many days they avoided family 
activities, how many days they avoided social activities, how many days they planned 
their activities around having a bathroom nearby, how many days they brought extra 
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clothes, how many days they dressed to accommodate their bleeding, and how concerned 
they were about staining their clothes.  
 Three questions (13, 19, and 20) made up the irregularity section. These questions 
asked women about when would they carried sanitary products, how predictable the start 
date of their period was, and how predictable the end date of their period was. Question 8 
was used to determine pain related to the period.    
 
Data Analysis 
Questions were answered in the form of multiple-choice format. Data from the 
questionnaires were input into the REDcap database. For the study, questions from the 
Baseline Health Form were included for analysis based on how relevant they were in 
answering the study aims. Questions from the Baseline Health Form included for analysis 
included questions 1-6, 8, 11-14, 17-18, and 20-22. Answers within the SF-36 and the 
MBQ each corresponded to a predetermined score to yield a total score for the survey. 
Both the SF-36 and the MBQ were scored out of a total of 100 points.  
Data were then coded and analyzed. Values were indicated to compare women 
with heavy/regular bleeding patterns to women with heavy/irregular bleeding patterns. 
Heavy/regular was designated by answers from the Baseline Health Form that 
corresponded to Q01 = YES and Q03 = NO; heavy/irregular was designated by answers 
to the Baseline Health Form that corresponded to Q01 = YES and Q03 = YES. Body 
mass index (BMI) was calculated by dividing the subject’s reported weight in kilograms 
by the square of the subject’s reported height in meters. 
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Shell tables were created and organized in Microsoft Excel 2016 (Microsoft 
Corporation, Redmond, WA) (25). Values were then uploaded to STATA version 13.1 
(StataCorp LLC, College Station, TX) to compare responses between heavy/regular and 
heavy/irregular groups (26). Questions with categorical variables were converted into 
proportions for each group being studied. Open-ended questions which yielded numerical 
values were analyzed by deriving the mean, standard deviation, median, range, and 
interquartile range (IQR). 
 The derived p-values were calculated using three statistical methods: Fisher’s 
exact test, T-test, and Wilcoxon rank-sum. The method by which each p-value was 
calculated was denoted in the tables. The Fisher’s test was used because it was applicable 
to small sample sizes. A p £ 0.05 was used for the Fisher’s exact test. The T-test was 
used because it has been applicable to determining if two sets of data are statistically 
different. A p £ 0.05 was used for these calculations. The Wilcoxon rank-sum was used 
because it allows for comparison between two sample groups and it can assess how the 
mean ranks differ in a population. A p £ 0.05 was used for these calculations.  
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RESULTS 
 Of the women who underwent endometrial ablations at the WIH surgical services 
center, 63 patients were enrolled in the study. These participants consented and 
completed the Baseline Health Form, the SF-36, and the MBQ. The retention rate (Table 
1) for participants in the study diminished at each scheduled follow-up visit. At the 3-
month follow-up visit, the retention rate was 41% (n = 26); at the 6-month follow-up 
visit, the retention rate fell to 33% (n = 21); and by the 1-year follow-up visit, the 
retention rate reached a low of 23% (n = 15). Participants who did not complete the 
follow-up visits either withdrew from the study, were unable to be contacted, or did not 
respond to follow-up attempts.  
 
 
Table 1. Summary of Participant Retention Rate. 
Results are tabulated based on the participants who completed follow-up visits. 
Variable Total 
n  =  63 n (%) 
Baseline Participants 63 (100%) 
3-Month Visit Participants 26 (41%) 
6-Month Visit Participants 21 (33%) 
1-Year Visit Participants 15 (23%) 
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Baseline Health Form: Self-Reported Bleeding Patterns 
Survey response data are presented in Table 2. 
 
Q01: Are your periods currently heavy? 
Of the women surveyed, 95.2% (n = 60) indicated that they experienced heavy bleeding 
during their periods. Only 4.8% (n = 3) responded “No,” indicating no heavy bleeding 
was present. 
 
Q02: How long have your periods been heavy?  
Women who indicated that their periods had been heavy for three months or less made up 
1.7% (n = 1) of the participants. Heavy bleeding lasting for three to six months was 
indicated by 5.1% (n = 3) of the participants. Periods that had been heavy for the last six 
months to one year were reported by 13.6% (n = 8) of the women. Heavy bleeding that 
had been present for the last one to two years was found in 18.6% (n = 11) of the 
participants. A majority of participants, 61% (n = 36) self-reported heavy bleeding that 
had been present for the last two or more years.  
 
Q03: Are your periods currently irregular? 
Of the women surveyed, 39.7% (n = 25) indicated “No,” that their periods were not 
irregular. Women who responded “Yes,” that their periods were irregular, made up 
60.3% (n = 38) of the participants. 
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Q04: How long have your periods been irregular? 
Women who indicated that their periods had been irregular for three months or less made 
up 5.4% (n = 2) of the participants. Irregular bleeding lasting for three to six months was 
indicated by 8.1% (n = 3). Periods that had been irregular for the last six months to one 
year were reported by 18.9% (n = 7) of women. Irregular bleeding that had been present 
for the last one to two years was found in 29.7% (n = 11) of participants. Self-reported 
irregular bleeding that had been present for the last two or more years was found in 
37.8% (n = 14) of women surveyed.  	  
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Table 2. Patient Self-Reported Bleeding Patterns. 
Results were tabulated from the answers given on the Baseline Health Form.  
Variable Total 
 n (%) 
01. Are your periods currently heavy? 
      
No 
Yes 
 
 
 
3 (4.8) 
60 (95.2) 
02. How long have your periods been heavy? 
      
<3 months 
3-6 months 
6 months – 1 year 
1-2 years 
2+ years 
 
 
 
1 (1.7) 
3 (5.1) 
8 (13.6) 
11 (18.6) 
36 (61.0) 
03. Are your periods currently irregular? 
      
No 
Yes 
 
 
 
25 (39.7) 
38 (60.3) 
04. How long have your periods been irregular? 
      
<3 months 
3-6 months 
6 months – 1 year 
1-2 years 
2+ years 
 
 
 
2 (5.4) 
3 (8.1) 
7 (18.9) 
11 (29.7) 
14 (37.8) 
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Baseline Health Form: Heavy/Regular Versus Heavy/Irregular 
Survey response data are presented in Table 3. 
 
Based on the participant self-reported bleeding patterns of the 63 women, 25 indicated 
they experienced heavy/regular bleeding, and 35 indicated they experienced 
heavy/irregular bleeding.  
 
Q05. In the past 2 years, have you tried any treatment for your period? 
From the heavy/regular group, 44% (n = 11) indicated “No,” and 56% (n = 14) indicated 
“Yes.” From the heavy/irregular group, 44.1% (n = 15) indicated “No,” and 55.9% (n = 
19) indicated “Yes.” 
 
Q06. Which of the following treatments for your period have you tried in the past two 
years? 
Women indicated they had tried all treatments in the last two years. Percentages did not 
sum up to 100%. 
Looking specifically at the heavy/regular group, 35.7% (n = 5) indicated they had tried 
oral contraceptive pills, 7.1 % (n = 1) indicated the use of the contraceptive patch, 50%  
(n = 7) had used NSAIDs, 7.1% (n = 1) had used oral progestin daily for 10-14 days a 
month, 35.7% (n = 5) indicated the use of oral progestin daily for 21 days a month, 7.1% 
(n = 1) indicated the use of the Depo-Provera injection, 35.7% (n = 5) had used the LNG-
IUS, 15.4% (n = 2) had had dilation and curettage, and 21.4% (n = 3) indicated other 
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treatments had been pursued. From this group, no participant indicated the use of 
Nuvaring or a GnRH agonist.  
Looking specifically at the heavy/irregular group, 36.8% (n = 7) indicated they had tried 
oral contraceptive pills, 5.9% (n = 1) had used Nuvaring in the past, 5.6%  (n = 1) had 
used a GnRH agonist, 42.1% (n = 8) had used NSAIDs, 22.2% (n = 4) had used oral 
progestin daily for 10-14 days a month, 11.1% (n = 2) indicated the use of oral progestin 
daily for 21 days a month, 16.7% (n = 3) indicated the use of the Depo-Provera injection, 
52.6% (n = 10) had used the LNG-IUS, and 5.6% (n = 1) indicated other treatments had 
been pursued. From this group, no participant indicated the use of the contraceptive patch 
or dilation and curettage. 
 
Q08. How many pregnancies resulted in delivery? 
The median number of pregnancies for the heavy/regular group was 2, with a range of 0-
4 pregnancies. For the heavy/irregular group, the median number of pregnancies was also 
2, with a range of 0-3 pregnancies. 
 
Q11. Have you been told by a healthcare provider that you have endometrial hyperplasia? 
For the heavy/regular group, 76% (n = 19) indicated “No,” 8% (n = 2) responded “Yes,” 
and 16% (n = 4) answered “Don’t know.” For the heavy/irregular group, 74.3% (n = 26) 
indicated “No,” 11.4% (n = 4) responded “Yes,” and 14.3% (n = 5) answered “Don’t 
know.”  
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Q12a. Have you ever had an endometrial biopsy? 
For the heavy/regular group, 20% (n = 5) indicated “No,” 60% (n = 15) responded “Yes,” 
and 20% (n = 5) answered “Don’t know.” For the heavy/irregular group, 18.2% (n = 6) 
indicated “No,” 66.7% (n = 22) responded “Yes,” and 15.2% (n = 5) answered “Don’t 
know.”  
 
Q12b. Have you ever had a D&C unrelated to pregnancy? 
For the heavy/regular group, 84% (n = 21) indicated “No,” 8% (n = 2) responded “Yes,” 
and 8% (n = 2) answered “Don’t know.” For the heavy/irregular group, 67.7% (n = 23) 
indicated “No,” 20.6% (n = 7) responded “Yes,” and 11.8% (n = 4) answered “Don’t 
know.”  
 
Q13a. Have you ever had an endometrial polyp? 
Of the heavy/regular group, 88% (n = 22) indicated “No,” and 12% (n = 3) responded 
“Yes.” For the heavy/irregular group, 84.9% (n = 28) indicated “No,” and 15.2% (n = 5) 
responded “Yes.”  
 
Q14a. Have you had tubal sterilization? 
In the heavy/regular group, 76% (n = 19) indicated “No,” and 24% (n = 6) responded 
“Yes.” For the heavy/irregular group, 50% (n = 17) indicated “No,” and 50% (n = 17) 
responded “Yes.”  
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BMI (kg/m2) 
For the heavy/regular group, the mean BMI was 28.4 kg/m2, with a standard deviation of 
5.2. The median BMI was 28.1 kg/m2, with a range from 20.3 kg/m2 to 40.5 kg/m2. For 
the heavy/irregular group, the mean BMI was 29.7 kg/m2, with a standard deviation of 
5.7. The median BMI was 28.4 kg/m2, with a range from 21.3 kg/m2 to 41.7 kg/m2. 
 
BMI, categorical (kg/m2) 
For the heavy/regular group, women with a BMI of less than 25 kg/m2 made up 25% (n = 
6) of participants. BMI’s values ranging from 25 kg/m2 to less than 30 kg/m2 constituted 
37.5% (n = 9).  Participants with a BMI of 30 kg/m2 to less than 40 kg/m2 were 33.3% (n 
= 8) of the group. Women with a BMI of 40 kg/m2 to less than 50 kg/m2 were 4.2% (n = 
1).  
For the heavy/irregular group, women with a BMI of less than 25 kg/m2 made up 20.6% 
(n = 7) of participants. BMI’s values ranging from 25 kg/m2 to less than 30 kg/m2 
constituted 41.2% (n = 14).  Participants with a BMI of 30 kg/m2 to less than 40 kg/m2 
were 32.4% (n = 11) of the group. Women with a BMI of 40 kg/m2 to less than 50 kg/m2 
were 5.9% (n = 2).  
 
Q17. Ethnicity 
Reported ethnicities for the heavy/regular group indicated 4.2% (n = 1) identified as 
Hispanic/Latino and 91.7% (n = 22) identified as not Hispanic/Latino. Of the total 
participants, only 4.2% (n = 1) choose not to answer. 
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In the heavy/irregular group, 22.9% (n = 8) reported their ethnicity as Hispanic/Latino, 
68.6% (n = 24) reported they were not Hispanic/Latino, and 8.6% (n = 3) chose not to 
answer. 
 
Q18. Race 
When the heavy/regular group was broken down by race, 4.2% (n = 1) listed American 
Indian or Alaskan Native, 4.2% (n = 1) indicated Asian, 83.3% (n = 20) listed their race 
as White, 4.2% (n = 1) indicated “I do not know,” and 4.2% (n = 1) choose not to answer. 
In the heavy/irregular group, 3.2% (n = 1) indicated they were American Indian or 
Alaskan Native, 80.7% (n = 25) answered White, 6.5% (n = 2) chose “I do not know,” 
and 9.6% (n = 3) preferred not to answered the question.  
 
Race (Collapsed) 
When race was collapsed to indicate “White,” “Other,” or “I do not want to answer” the 
derived values were similar. In the heavy/regular group, 83.3% (n = 20) of the women 
indicated “White”, 12.5% (n = 3) indicated their race as “Other,” and 4.2% (n = 1) did 
not answer. In the heavy/irregular group, 80.7% (n = 25) listed “White,” 9.7% (n = 3) 
were an “Other” race, and 9.7% (n = 3) chose not to answer.  
 
20. Marital Status 
Looking at participant marital status, those in the heavy/regular group had an 80% (n = 
20) rate of being married. Twenty percent (n = 5) reported that they were divorced or 
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separated. Women in the heavy/irregular group reported a 65.7% (n = 23) rate of being 
married, and a 17.1% (n = 6) rate of being divorced or separated. Of the individuals in the 
group, 8.6% (n = 3) indicated they were living with a partner, and 8.6% (n = 3) indicated 
they were never married.  
 
21. Employment Situation 
Women were able to choose various answers to describe their current employment 
situation. As a result of this, the percentages did not sum up to 100%. 
Women in the heavy/regular group reported an 88% (n = 22) rate of working full time. 
Eight percent (n = 2) indicated they were working part time, 4% (n = 1) said they were on 
illness/sick leave, and another 8% (n = 2) reported “Other” as their employment situation.  
In the heavy/irregular group, 71.4% (n = 25) reported they were working full time, 14.3% 
(n = 5) indicated they were working part time. Women who identified as a full-time 
homemaker were 8.6% (n = 3) of the participants. Students made up 2.9% (n = 1) of the 
women surveyed, and “Other” made up 5.7% (n = 2). 
 
22. Education 
Breaking down each group by highest level of education shows that for women in the 
heavy/regular group, 12.5% (n = 3) completed 12th grade, 20.8% (n = 5) completed 
technical/trade school, 12.5% (n = 3) completed some college, 29.2% (n = 7) graduated 
from a four-year college, and 25% (n = 6) completed graduate/professional school.  
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For women in the heavy/irregular group, 2.9% (n = 1) attained a 9th – 11th grade 
education, 25.7% (n = 9) had a 12th grade education, 14.3% (n = 5) completed 
trade/technical school, 28.6% (n = 10) had some college education, 17.1% (n = 6) 
graduated from a four-year college, and 11.4% (n = 4) completed graduate/professional 
school.  						 	
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Table 3. Comparison of Demographic, Patient, and Surgical Characteristics 
Between Heavy/Regular and Heavy/Irregular Bleeding Patterns. 
Results were tabulated from the answers given on the Baseline Health Form. 
N = 60 Pre-Op Bleeding Pattern  
Variable Heavy/Regular 
(n = 25) 
Heavy/Irregular 
(n = 35) 
p-
value 
05. In the past 2 years, have you tried 
any treatment for your period? 
 
No 
Yes 
 
(n = 25) 
 
 
11 (44.0) 
14 (56.0) 
(n = 34) 
 
 
15 (44.1) 
19 (55.9) 
 
 
 
1.001 
06. Which of the following treatments 
for your period have you tried in the 
past two years? * 
 
Oral Contraceptive Pills 
Contraceptive Patch 
Nuvaring 
GnRH Agonist 
NSAIDs 
Oral Progestin (daily for 10-14 
days/month 
Oral Progestin (daily for 21 
days/month) 
Depo-Provera Injection 
Levonorgestrel-Intrauterine System 
Dilation and Curettage 
Other 
 
*Check all that apply question; 
percentages do not sum to 100% 
 
 
 
 
 
5 (35.7) 
1 (7.1) 
0 (--) 
0 (--) 
7 (50.0) 
1 (7.1) 
 
5 (35.7) 
 
1 (7.1) 
5 (35.7) 
2 (15.4) 
3 (21.4) 
 
 
 
 
7 (36.8) 
0 (--) 
1 (5.9) 
1 (5.6) 
8 (42.1) 
4 (22.2) 
 
2 (11.1) 
 
3 (16.7) 
10 (52.6) 
0 (--) 
1 (5.6) 
 
 
 
 
1.001 
0.441 
1.001 
1.001 
0.731 
0.361 
 
0.191 
 
0.611 
0.481 
0.171 
0.291 
08. How many pregnancies resulted in 
delivery? 
 
Median (Min-Max) 
 
(n = 24) 
 
 
2 (0-4) 
(n = 33) 
 
 
2 (0-3) 
 
 
 
0.592 
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11. Told by healthcare provider that 
you have endometrial hyperplasia? 
 
No 
Yes 
Don’t know 
 
 
 
 
19 (76.0) 
2 (8.0) 
4 (16.0) 
 
 
 
26 (74.3) 
4 (11.4) 
5 (14.3) 
 
 
 
1.001 
12a. Have you ever had an endometrial 
biopsy? 
 
No 
Yes 
Don’t know 
 
(n = 25) 
 
 
5 (20.0) 
15 (60.0) 
5 (20.0) 
(n = 33) 
 
 
6 (18.2) 
22 (66.7) 
5 (15.2) 
 
 
 
0.851 
12b. Have you ever had a D&C 
unrelated to pregnancy? 
 
No 
Yes 
Don’t know 
 
(n = 25) 
 
 
21 (84.0) 
2 (8.0) 
2 (8.0) 
(n = 34) 
 
 
23 (67.7) 
7 (20.6) 
4 (11.8) 
 
 
 
0.381 
13a. Have you ever had an endometrial 
polyp? 
 
No 
Yes 
 
(n = 25) 
 
 
22 (88.0) 
3 (12.0) 
(n = 33) 
 
 
28 (84.9) 
5 (15.2) 
 
 
 
1.001 
14a. Have you had tubal sterilization? 
 
No 
Yes 
 
(n = 25) 
 
19 (76.0) 
6 (24.0) 
(n = 34) 
 
17 (50.0) 
17 (50.0) 
 
 
0.0601 
BMI (kg/m2) 
 
Mean (SD) 
Median (Min-Max) 
 
(n = 24) 
 
28.4 (5.2) 
28.1 (20.3-40.5) 
(n = 34) 
 
29.7 (5.7) 
28.4 (21.3-
41.7) 
 
 
0.533 
BMI, categorical (kg/m2) 
 
<25 
25 - <30 
30 - <40 
40 - <50 
 
(n = 24) 
 
6 (25.0) 
9 (37.5) 
8 (33.3) 
1 (4.2) 
(n = 34) 
 
7 (20.6) 
14 (41.2) 
11 (32.4) 
2 (5.9) 
 
 
0.971 
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17. Ethnicity 
 
Hispanic / Latino 
Not Hispanic / Latino 
I do not want to answer 
 
(n = 24) 
 
1 (4.2) 
22 (91.7) 
1 (4.2) 
(n = 35) 
 
8 (22.9) 
24 (68.6) 
3 (8.6) 
 
 
0.111 
18. Race 
 
American Indian or Alaska Native 
Asian 
White 
I do not know 
I do not want to answer 
 
(n = 24) 
 
1 (4.2) 
1 (4.2) 
20 (83.3) 
1 (4.2) 
1 (4.2) 
(n = 31) 
 
1 (3.2) 
0 (--) 
25 (80.7) 
2 (6.5) 
3 (9.6) 
 
 
0.851 
Race (collapsed) 
 
     White 
     Other 
     I do not want to answer 
 
(n = 24) 
 
20 (83.3) 
3 (12.5) 
1 (4.2) 
(n = 31) 
 
25 (80.7) 
3 (9.7) 
3 (9.7) 
 
0.771 
20. Marital Status 
 
Married 
Living with Partner 
Never Married 
Divorced or Separated 
 
 
 
20 (80.0) 
0 (--) 
0 (--) 
5 (20.0) 
 
 
23 (65.7) 
3 (8.6) 
3 (8.6) 
6 (17.1) 
 
 
0.251 
21. Employment Situation* 
 
Working Full Time 
Working Part Time 
On Illness/Sick Leave 
Full-Time Homemaker 
Student 
Other 
 
*Check all that apply question; 
percentages do not sum to 100% 
 
 
 
22 (88.0) 
2 (8.0) 
1 (4.0) 
0 (--) 
0 (--) 
2 (8.0) 
 
 
 
25 (71.4) 
5 (14.3) 
0 (--) 
3 (8.6) 
1 (2.9) 
2 (5.7) 
 
 
0.201 
0.691 
0.421 
0.261 
1.001 
1.001 
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22. Education 
 
9th-11th Grade 
12th Grade 
Technical/Trade School 
Some College 
Completed 4-year College 
Graduate/Professional School 
 
(n = 24) 
 
0 (--) 
3 (12.5) 
5 (20.8) 
3 (12.5) 
7 (29.2) 
6 (25.0) 
(n = 35) 
 
1 (2.9) 
9 (25.7) 
5 (14.3) 
10 (28.6) 
6 (17.1) 
4 (11.4) 
 
 
0.271 
 
1Fisher’s exact test  
2T-test 
3Wilcoxon rank-sum 	  
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Menstrual Bleeding Questionnaire: Heavy/Regular Versus Heavy/Irregular 
Survey response data are presented in Table 4. 
 
Q00. During the past month, did you have any bleeding? 
One hundred percent (n = 25) of the women in the heavy/regular group responded “Yes.” 
Women in the heavy/irregular group had a 91.4% (n = 32) rate of bleeding in the past 
month, and 8.6% (n = 3) indicated “No,” that they had not experienced bleeding in the 
past month (p = 0.26). Of the women who responded “No,” questions 1-11 were skipped, 
whereas women who answered “Yes” had to answer these questions. 
 
Q01. During the past month, how would you describe your periods? 
Within the heavy/regular group, 68% (n = 17) of women indicated that they experienced 
“Very Heavy” bleeding, 28% (n = 7) had “Heavy” bleeding, and 4% (n = 1) had “Light” 
bleeding. Participants in the heavy/irregular group had a 43.8% (n = 14) rate of “Very 
Heavy” bleeding. “Heavy” bleeding was found in 34.4% (n = 11) of women, “Moderate” 
bleeding was seen in 15.6% (n = 5) of the participants, and only 6.3% (n = 2) had “Light” 
bleeding.  (p = 0.10)  
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Q02. On the heaviest day of bleeding during the past month, how many high absorbency 
sanitary products did you soak? 
For the heavy/regular group, 12% (n = 3) soaked “1-4” products a day, 56% (n = 14) 
needed “5-8” products a day, 20% (n = 5) used “9-12” products a day, 8% (n = 2) soaked 
“13-16” products a day, and 4% (n = 1) required “16+” products in one day.  
Of the heavy/irregular participants, 6.3% (n = 2) soaked “0” products a day, 21.9% (n = 
7) soaked “1-4” products a day, 18.8% (n = 6) soaked “5-8” products a day, 37.5% (n = 
12) used “9-12” products a day, 3.1% (n = 1) required “13-16” products a day, and 12.5% 
(n = 4) soaked “16+” products a day.  (p = 0.04)  
 
Q03. During the past month, how often did you need to wear an incontinence brief or 
more than one high absorbency sanitary product at a time to contain your bleeding? 
Twenty percent (n = 5) in the heavy/regular group indicated that they “Never” required 
the use of an incontinence brief or high absorbency sanitary product. The use of these 
products “1-3 times” in the past month was found in 32% (n = 8) of those surveyed. The 
use of “4-6 times” in the past month was found in 20% (n = 5) of participants, and it was 
also found to be 20% (n = 5) of women who required their use “7-10 times” in the last 
month. Women who had used them “11+ times” in the last month made up 8% (n = 2) of 
women in the group.  
When looking at the heavy/irregular group, 29% (n = 9) “Never” required use of these 
products in the past month. Women who had used an incontinence brief or high 
absorbency sanitary product “1-3 times” and “4-6 times” in the last month each reported 
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a 19.4% (n = 6) rate. Use of these products ranging “7-10 times” in the past month was 
reported at 16.1% (n = 5), and the use of “11+ times” was reported at 16.1% (n = 5).  
 
Q04. During the past month, how many times have you had an episode of bleeding that 
soaked through your “outer” clothes? 
Participants who reported 0 episodes, or “Never” soaking their clothes, made up 20% (n 
= 5) of the heavy/regular group. Episodes that amounted to “1-3 times” in the past month 
were experienced by 76% (n = 19) of the group. Only 4% (n = 1) experienced bleeding 
that soaked their clothes “4-6 times” in the last month.  
Of the women in the heavy/irregular group, 28.1% (n = 9) reported “Never” soaking their 
clothes in the past month. A majority of women in this group, 46.9% (n = 15), soaked 
their clothes “1-3 times” in the last month. Finally, 12.5% (n = 4) of women had these 
episodes “4-6 times,” and 12.5% (n = 4) had these episodes “6+ times” in the last month. 
(p = 0.09) 
 
Q05. During the past month, how many times did you need to get out of bed in the 
middle of the night to change your sanitary products? 
Women reporting “Never” having to get up in the past month to change sanitary products 
made up 12% (n = 3) of the heavy/regular group. Getting up “1-3 times” in the last month 
was reported by 64% (n = 16) of the group, “4-6 times” by 8% (n = 2), “7-10 times” by 
12% (n = 3), and “11+ times” by 4% (n = 1). 
	51 
In the heavy/irregular group, 21.9% (n = 7) reported “Never” having to get up during the 
night. Fifty percent (n = 16) indicated that they got out of bed “1-3 times” in the past 
month, 12.5% (n = 4) reported “4-6 times,” 6.3% (n = 2) reported “7-10 times,” and 9.4% 
(n = 3) reported “11+ times” in the past month.  (p = 0.66) 
 
Q06. During the past month, how many times did you pass blood clots? 
Participants belonging to the heavy/regular group responded that 20% (n = 5) passed 
blood clots “1-3 times” in the past month, 48% (n = 12) passed blood clots “4-6 times,” 
and 32% (n = 8) reported an occurrence “6+ times.” 
In the heavy/irregular group, 12.5% (n = 4) of the women reported “Never” passing blood 
clots in the past month. Twenty-five percent (n = 8) responded “1-3 times” in the past 
month, and 25% (n = 8) also reported “4-6 times.” Women with the maximum number of 
occurrences, “6+ times,” made up 37.5% (n = 12) of the group.  (p = 0.16) 
 
Q07. During the past month, how often did passing blood clots stain your clothing? 
Among heavy/regular participants, 40% (n = 10) indicated this event to “Never” have 
occurred in the past month. A frequency of “1-3 times” in the past month was found to be 
the case for 44% (n = 11) of women, whereas 16% (n = 4) reported an occurrence of “4-6 
times.” 
The heavy/irregular group reported a rate of “Never” at 34.4% (n = 11). Women 
indicating an incidence of “1-3 times” in the past month made up 46.9% (n = 15) of this 
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group. Participants who experienced blood clot staining “4-6 times” in the past month 
were 12.5% (n = 4), and participants who counted “6+ times” were 6.3% (n = 2).  
 
Q08. Fill the following statement: During the past month, my period was associated 
with... 
Twelve percent (n = 3) of the women in the heavy/regular group reported “No pain” 
associated with their last period. Although “Slight pain” was indicated by 20% (n = 5), 
and “Moderate pain” by 48% (n = 12), “Severe pain” was selected by 20% (n = 5) of the 
group. “No pain” was reported by 9.4% (n = 3) of the women in the heavy/irregular 
group. “Slight pain” was found in 9.4% (n = 3), “Moderate pain” was found in 43.8% (n 
= 14), and “Severe pain” was found in 37.5% (n = 12) of women.  (p = 0.46) 
 
Q09. During the past month, how many weeks did your period last? 
A majority of participants in the heavy/regular group tended to experience periods lasting 
from 0-2 weeks. Within this subgroup, 52% (n = 13) reported a period lasting “1 week or 
less out of 4” and 40% (n = 10) indicated a period lasting “More than 1 week, less than 2 
weeks out of 4.” Only 8% (n = 2) of women in this group were found to have a period 
lasting “More than 3 weeks out of 4.” 
Women in the heavy/irregular group tended to report a wider range of lengths for their 
periods. In this group, 28.1% (n = 9) of women indicated a period lasting “1 week or less 
out of 4.” Another 28.1% (n = 9) also reported a period lasting “More than 1 week, less 
than 2 weeks out of 4.” A period that lasted “More than 2 weeks, less than 3 weeks out of 
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4” was seen in 21.9% (n = 7), a period that lasted “More than 3 weeks out of 4” was also 
seen in 21.9% (n = 7).  (p = 0.02)  
 
Q10. During the past month, on how many days do you think your work at your job 
suffered because you were bleeding? 
Women in the heavy/regular group tended to report less interference in their work, with 
36% (n = 9) indicating “Never, my bleeding does not affect my work,” and 60% (n = 15) 
saying that bleeding interfered at work “1-3 days” in the past month. Only 4% (n = 1) 
reported an interference of “4-8 days.” 
Bleeding was found to be more of an issue among the heavy/irregular group. Although 
43.8% (n = 14) indicated a response of “Never, my bleeding does not affect my work,” 
subsequent responses ranged from the minimum number of days to the maximum. 
Women who reported bleeding to have affected their work in the past month for “1-3 
days” were 37.5% (n = 12) of the group. A response of “4-8 days” was reported by 9.4% 
(n = 3) of the women, “9-12 days” was reported by 6.3% (n = 2), and “13+ days” by 
3.1% (n = 1).  (p = 0.36) 
 
Q11. During the past month, on how many days did you miss work because you were 
bleeding? 
Sixty percent (n = 15) of women in the heavy/regular group reported “Never, my 
bleeding does not affect my work,” which is very similar to the 65.6% (n = 21) of women 
who reported the same answer in the heavy/irregular group. Of the women in the 
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heavy/regular group who indicated they had to miss days of work, 36% (n = 9) missed 
“1-3 days” and 4% (n = 1) missed “4-8 days.” Twenty-five percent (n = 8) of women in 
the heavy/irregular group reported missing “1-3 days” of work, 6.3% (n = 2) missed “4-8 
days,” and only 3.1% (n = 1) missed “9-12 days” of work.  
 
Q12. During the past month, how many days did you avoid family activities when you 
thought you were bleeding? 
Values in this category were found to be very similar between both groups of 
participants. In the heavy/regular group, 36% (n = 9) indicated a response of “Never,” 
48% (n = 12) responded “1-3 days,” 12% (n = 3) said “4-8 days,” and 4% (n = 1) avoided 
activities “9-12 days.” Women in the heavy/irregular group recorded “Never” at 38.2% (n 
= 13), “1-3 days” at 38.2% (n = 13), “4-8 days” at 11.8% (n = 4), “9-12 days” at 8.8% (n 
= 3), and the maximum of “13+ days” at 2.9% (n = 1).  
 
Q13. During the past month, when would you carry sanitary products with you? 
More women of the heavy/irregular group were found to be affected, with 87.9% (n = 29) 
indicating “Every day, in case I had bleeding” as opposed to the heavy/regular group 
reporting a rate of 64% (n = 16). Among heavy/regular participants, 20% (n = 5) reported 
“On days when I had bleeding and on days when I guessed that I might have bleeding,” 
as opposed to heavy/irregular women who indicated this response 9.1% (n = 3) of the 
time. Sixteen percent (n = 4) of women in the heavy/regular group carried sanitary 
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products “Only on the days that I had bleeding” as opposed to 3% (n = 1) of women in 
the heavy/irregular group.  (p = 0.09) 
 
Q14. During the past month, how many days did you avoid social activities when you 
thought you would be bleeding? 
When it came to avoiding social activities, 40% (n = 10) of heavy/regular women 
indicated this was “Never” an issue, 52% (n = 13) reported “1-3 days,” and 8% (n = 2) 
reported “4-8 days.” Among heavy/irregular women, 35.3% (n = 12) indicated “Never,” 
44.1% (n = 15) reported “1-3 days,” 8.8% (n = 3) reported “4-8 days,” 8.8% (n = 3) 
reported “9-12 days,” and only 2.9% (n = 1) had the maximum of “13+days.” 
 
Q15. During the past month, how many days did you plan your activities based on 
whether or not there was a bathroom nearby? 
Women in the heavy/regular group overwhelmingly indicated that this was “Never” a 
concern with 48% (n = 12) of them, and when it was, 48% (n = 3) answered “1-3 days.” 
Only 4% (n = 1) of women in this group indicated “13+ days” for planning to be close to 
a bathroom. 
Although more than half of the heavy/irregular women, 52.9% (n = 18), reported this was 
“Never” a concern, the other 47.1% of women in this group had to take this into account 
from 1 to 13 or more days. Breaking them down by subgroup, 26.5% (n = 9) reported “1-
3 days,” 11.8% (n = 4) indicated “4-8 days,” 5.9% (n = 2) answered “9-12 days,” and 
2.9% (n = 1) selected the maximum of “13+ days.”  (p = 0.15) 
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Q16. During the past month, how many days did you bring extra clothes with you in case 
you had staining from your period? 
This was “Never” a concern for 60% (n = 15) of heavy/regular women and 44.1% (n = 
15) of heavy/irregular women. Twenty-eight percent (n = 7) of heavy/regular women 
brought extra clothes “1-3 days” in the past month, 4% (n = 1) did so “4-6 days,” and 8% 
(n = 2) “6+ days.” In the heavy/irregular group, 44.1% (n = 15) of the women carried 
extra clothes “1-3 days” in the past month, 5.9% (n = 2) reported “4-6 days,” and 5.9% (n 
= 2) reported “6+ days.” 
 
Q17. During the past month, how many days did you choose what to wear based on 
whether or not you were bleeding? 
Among participants with heavy/regular bleeding, a majority, 68% (n = 17), indicated “1-3 
days,” followed by 16% (n = 4) reporting “4-8 days.” Furthermore, 4% (n = 1) reported 
“Never,” 4% (n = 1) indicated “9-12 days,” and 8% (n = 2) answered “13+ days.” 
For women with heavy/irregular bleeding, 40% (n = 14), indicated “1-3 days,” followed 
by 25.7% (n = 9) reporting “4-8 days.” Looking at other responses, 17.1% (n = 6) 
reported “Never,” 11.4% (n = 4) indicated “9-12 days,” and 5.7% (n = 2) answered “13+ 
days.”  (p = 0.21) 
 
Q18. Overall concern about bleeding staining your clothes. 
Participants reported their concern on a scale of 0-10, with 0 being no concern and 10 
being extremely concerned. Women in the heavy/regular group reported a mean concern 
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of 6.3 with a standard deviation of 2.3. The median concern was 6, with a range of 1-10. 
The IQR was 5 to 8. 
Among women of heavy/irregular bleeding, the mean concern was 6.2 with a standard 
deviation of 3.6. The median concern was 7, with a range of 0-10. The IQR was 3 to 10. 
 
Q19. Would you say that your period start date was... 
Among heavy/regular participants, 28% (n = 7) reported “Completely predictable,” 68% 
(n = 17) indicated “Somewhat predictable,” and only 4% (n = 1) answered “Not at all 
predictable.” 
Among heavy/irregular participants, 5.7% (n = 2) reported “Completely predictable,” and 
34.3% (n = 12) indicated “Somewhat predictable,” but 60% (n = 21) answered “Not at all 
predictable.”  (p = <0.001) 
 
Q20. Would you say your period end date was... 
Among heavy/regular participants, 16% (n = 4) reported “Completely predictable,” 48% 
(n = 12) indicated “Somewhat predictable,” and 36% (n = 9) answered “Not at all 
predictable.” 
Among heavy/irregular participants, 5.7% (n = 2) reported “Completely predictable,” and 
22.9% (n = 8) indicated “Somewhat predictable,” but 71.4% (n = 25) answered “Not at 
all predictable.”  (p = 0.02) 
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Bleeding Domain Score 
Among heavy/regular participants, the mean score of this domain was 13.3 with a 
standard deviation of 4.0. The median was 12.0 with a range of 8.0 to 23.0. The IQR was 
between 11.0 to 15.0.  
Heavy/irregular participants had a mean score of 13.8 with a standard deviation of 5.9. 
The median was 13.5 with a range of 3.0 to 27.0. The IQR was between 9.0 to 19.0.  (p = 
0.67) 
 
Irregularity Domain Score 
Among heavy/regular participants, the mean score of this domain was 3.4 with a standard 
deviation of 1.6. The median was 3.0 with a range of 0 to 6.0. The IQR was between 3.0 
to 5.0.  
Heavy/irregular participants had a mean score of 4.9 with a standard deviation of 1.3. The 
median was 5.0 with a range of 2.0 to 6.0. The IQR was between 4.0 to 6.0.  (p = <0.001) 
 
Pain Domain Score 
Among heavy/regular participants, the mean score of this domain was 1.8 with a standard 
deviation of 0.93. The median was 2.0 with a range of 0 to 3.0. The IQR was between 1.0 
to 2.0.  
Heavy/irregular participants had a mean score of 2.1 with a standard deviation of 0.93. 
The median was 2.0 with a range of 0.0 to 3.0. The IQR was between 2.0 to 3.0.  (p = 
0.18) 
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Quality of Life Score 
Among heavy/regular participants, the mean score of this domain was 11.6 with a 
standard deviation of 5.1. The median was 11.0 with a range of 3.0 to 23.0. The IQR was 
between 8.0 to 14.0.  
Heavy/irregular participants had a mean score of 12.9 with a standard deviation of 7.4. 
The median was 11.0 with a range of 0.0 to 35.0. The IQR was between 8.0 to 17.0.  (p = 
0.66) 
 
Total MBQ Score 
Among heavy/regular participants, the mean score of this domain was 39.7 with a 
standard deviation of 13.4. The median was 36.9 with a range of 14.9 to 67.3. The IQR 
was between 33.0 to 46.2.  
Heavy/irregular participants had a mean score of 45.5 with a standard deviation of 15.2. 
The median was 42.2 with a range of 23.8 to 93.7. The IQR was between 34.9 to 50.2.  (p 
= 0.14) 
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Table 4. Pre-Op MBQ Bleeding Patterns. 
Results were tabulated based on answers from the Menstrual Bleeding Questionnaire. 
N = 60 Pre-Op Bleeding Pattern  
Variable Heavy/Regular 
(n = 25) 
Heavy/Irregular 
(n = 35) 
p-value 
00. During the past month, did you 
have any bleeding? 
 
No 
Yes 
 
 
 
 
0 (--) 
25 (100) 
 
 
 
3 (8.6) 
32 (91.4) 
 
 
 
0.261 
01. During the past month, how 
would you describe your periods? 
 
Light 
Moderate 
Heavy 
Very Heavy 
 
(n = 25) 
 
 
1 (4.0) 
0 (--) 
7 (28.0) 
17 (68.0) 
(n = 32) 
 
 
2 (6.3) 
5 (15.6) 
11 (34.4) 
14 (43.8) 
 
 
 
0.101 
02. On the heaviest day of bleeding 
during the past month, how many 
high absorbency sanitary 
products did you soak? 
 
0 
1-4 
5-8 
9-12 
13-16 
16+ 
 
(n = 25) 
 
 
 
 
0 (--) 
3 (12.0) 
14 (56.0) 
5 (20.0) 
2 (8.0) 
1 (4.0) 
(n = 32) 
 
 
 
 
2 (6.3) 
7 (21.9) 
6 (18.8) 
12 (37.5) 
1 (3.1) 
4 (12.5) 
 
 
 
 
 
0.041 
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03. During the past month, how often 
did you need to wear an 
incontinence brief or more than 
one high absorbency sanitary 
product at a time to contain your 
bleeding? 
 
Never 
1-3 times 
4-6 times 
7-10 times 
11+ times 
 
(n = 25) 
 
 
 
 
 
 
5 (20.0) 
8 (32.0) 
5 (20.0) 
5 (20.0) 
2 (8.0) 
(n = 31) 
 
 
 
 
 
 
9 (29.0) 
6 (19.4) 
6 (19.4) 
5 (16.1) 
5 (16.1) 
 
 
 
 
 
 
 
0.741 
04. During the past month, how many 
times have you had an episode of 
bleeding that soaked through your 
“outer” clothes? 
 
Never 
1-3 times 
4-6 times 
6+ times 
 
(n = 25) 
 
 
 
 
5 (20.0) 
19 (76.0) 
1 (4.0) 
0 (--) 
(n = 32) 
 
 
 
 
9 (28.1) 
15 (46.9) 
4 (12.5) 
4 (12.5) 
 
 
 
 
 
0.091 
05. During the past month, how many 
times did you need to get out of 
bed in the middle of the night to 
change your sanitary products? 
 
Never  
1-3 times 
4-6 times 
7-10 times 
11+ times 
 
(n = 25) 
 
 
 
 
3 (12.0) 
16 (64.0) 
2 (8.0) 
3 (12.0) 
1 (4.0) 
(n = 32) 
 
 
 
 
7 (21.9) 
16 (50.0) 
4 (12.5) 
2 (6.3) 
3 (9.4) 
 
 
 
 
 
0.661 
06. During this past month, how 
many times did you pass blood 
clots? 
 
Never 
1-3 times 
4-6 times 
6+ times 
 
(n = 25) 
 
 
 
0 (--) 
5 (20.0) 
12 (48.0) 
8 (32.0) 
(n = 32) 
 
 
 
4 (12.5) 
8 (25.0) 
8 (25.0) 
12 (37.5) 
 
 
 
 
0.161 
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07. During the past month, how often 
did passing blood clots stain your 
clothing? 
 
Never 
1-3 times 
4-6 times 
6+ times 
 
(n = 25) 
 
 
 
10 (40.0) 
11 (44.0) 
4 (16.0) 
0 (--) 
(n = 32) 
 
 
 
11 (34.4) 
15 (46.9) 
4 (12.5) 
2 (6.3) 
 
 
 
 
0.791 
08. Fill in the following statement: 
During the past month, my period 
was associated with... 
 
No pain 
Slight pain 
Moderate pain 
Severe pain 
 
(n = 25) 
 
 
 
3 (12.0) 
5 (20.0) 
12 (48.0) 
5 (20.0) 
(n = 32) 
 
 
 
3 (9.4) 
3 (9.4) 
14 (43.8) 
12 (37.5) 
 
 
 
 
0.461 
09. During the past month, how many 
weeks did your period last? 
 
1 week or less out of 4 
More than 1 week, less than 2 
weeks out of 4 
More than 2 weeks, less than 3 
weeks out of 4 
More than 3 weeks out of 4 
 
(n = 25) 
 
 
13 (52.0) 
10 (40.0) 
 
0 (--) 
 
2 (8.0) 
(n = 32) 
 
 
9 (28.1) 
9 (28.1) 
 
7 (21.9) 
 
7 (21.9) 
 
 
 
0.021 
10. During the past month, how many 
days do you think your work at 
your job suffered because you 
were bleeding? 
 
Never, my bleeding does not 
affect my work 
1-3 days 
4-8 days 
9-12 days 
13+ days 
(n = 25) 
 
 
 
 
9 (36.0) 
 
15 (60.0) 
1 (4.0) 
0 (--) 
0 (--) 
 
(n = 32) 
 
 
 
 
14 (43.8) 
 
12 (37.5) 
3 (9.4) 
2 (6.3) 
1 (3.1) 
 
 
 
 
 
0.361 
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11. During the past month, how many 
days did you miss work because 
you were bleeding? 
 
Never, my bleeding does not 
affect my work 
1-3 days 
4-8 days 
9-12 days 
 
(n = 25) 
 
 
 
15 (60.0) 
 
9 (36.0) 
1 (4.0) 
0 (--) 
(n = 32) 
 
 
 
21 (65.6) 
 
8 (25.0) 
2 (6.3) 
1 (3.1) 
 
 
 
 
0.811 
12. During the past month, how many 
days did you avoid family 
activities when you thought you 
were bleeding? 
 
Never 
1-3 days 
4-8 days 
9-12 days 
13+ days 
 
(n = 25) 
 
 
 
 
9 (36.0) 
12 (48.0) 
3 (12.0) 
1 (4.0) 
0 (--) 
(n = 34) 
 
 
 
 
13 (38.2) 
13 (38.2) 
4 (11.8) 
3 (8.8) 
1 (2.9) 
 
 
 
 
 
0.951 
13. During the past month, when 
would you carry sanitary products 
with you? 
 
Every day, in case I had any 
bleeding 
On days when I had bleeding and 
on days when I guessed that I 
might have bleeding 
Only on the days that I had 
bleeding 
 
(n = 25) 
 
 
 
16 (64.0) 
 
5 (20.0) 
 
 
4 (16.0) 
(n = 33) 
 
 
 
29 (87.9) 
 
3 (9.1) 
 
 
1 (3.0) 
 
 
 
 
0.091 
14. During the past month, how many 
days did you avoid social 
activities when you thought you 
would be bleeding? 
 
Never 
1-3 days 
4-8 days 
9-12 days 
13+ days 
 
(n = 25) 
 
 
 
 
10 (40.0) 
13 (52.0) 
2 (8.0) 
0 (--) 
0 (--) 
(n = 34) 
 
 
 
 
12 (35.3) 
15 (44.1) 
3 (8.8) 
3 (8.8) 
1 (2.9) 
 
 
 
 
 
0.621 
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15. During the past month, how many 
days did you plan your activities 
based on whether or not there was 
a bathroom nearby? 
 
Never 
1-3 days 
4-8 days 
9-12 days 
13+ days 
 
(n = 25) 
 
 
 
 
12 (48.0) 
12 (48.0) 
0 (--) 
0 (--) 
1 (4.0) 
(n = 34) 
 
 
 
 
18 (52.9) 
9 (26.5) 
4 (11.8) 
2 (5.9) 
1 (2.9) 
 
 
 
 
 
0.151 
16. During the past month, how many 
days did you bring extra clothes 
with you in case you had staining 
from your period? 
 
Never 
1-3 days 
4-6 days 
6+ days 
 
(n = 25) 
 
 
 
 
15 (60.0) 
7 (28.0) 
1 (4.0) 
2 (8.0) 
(n = 34) 
 
 
 
 
15 (44.1) 
15 (44.1) 
2 (5.9) 
2 (5.9) 
 
 
 
 
 
0.631 
17. During the past month, how many 
days did you choose what to wear 
based on whether or not you were 
bleeding? 
 
Never 
1-3 days 
4-8 days 
9-12 days 
13+ days 
 
 
 
 
 
 
1 (4.0) 
17 (68.0) 
4 (16.0) 
1 (4.0) 
2 (8.0) 
 
 
 
 
 
6 (17.1) 
14 (40.0) 
9 (25.7) 
4 (11.4) 
2 (5.7) 
 
 
 
 
 
0.211 
18. Overall concern about bleeding 
staining your clothes 
 
Mean (SD) 
Median (Min-Max) 
IQR (Q1-Q3) 
 
(n = 25) 
 
 
6.3 (2.3) 
6 (1-10) 
(5-8) 
(n = 33) 
 
 
6.2 (3.6) 
7 (0-10) 
(3-10) 
 
 
 
 
0.872 
	65 
19. Would you say that your period 
start date was... 
 
Completely predictable 
Somewhat predictable 
Not at all predictable 
 
 
 
 
7 (28.0) 
17 (68.0) 
1 (4.0) 
 
 
 
2 (5.7) 
12 (34.3) 
21 (60.0) 
 
 
 
<0.0011 
20. Would you say your period end 
date was... 
 
Completely predictable 
Somewhat predictable 
Not at all predictable 
 
 
 
 
4 (16.0) 
12 (48.0) 
9 (36.0) 
 
 
 
2 (5.7) 
8 (22.9) 
25 (71.4) 
 
 
 
0.021 
Bleeding Domain Score 
 
     Mean (SD) 
     Median (Min-Max) 
     IQR (Q1-Q3) 
 
(n = 25) 
 
13.3 (4.0) 
12.0 (8.0-23.0) 
(11.0-15.0) 
(n = 32) 
 
13.8 (5.9) 
13.5 (3.0-27.0) 
(9.0-19.0) 
 
 
0.672 
Irregularity Domain Score 
 
     Mean (SD) 
     Median (Min-Max) 
     IQR (Q1-Q3) 
 
 
 
3.4 (1.6) 
3.0 (0-6.0) 
(3.0-5.0) 
 
 
4.9 (1.3) 
5.0 (2.0-6.0) 
(4.0-6.0) 
 
 
<0.0013 
Pain Domain Score 
 
     Mean (SD) 
     Median (Min-Max) 
     IQR (Q1-Q3) 
 
(n = 25) 
 
1.8 (0.93) 
2.0 (0-3.0) 
(1.0-2.0) 
(n = 32) 
 
2.1 (0.93) 
2.0 (0-3.0) 
(2.0-3.0) 
 
 
0.182 
Quality of Life Score 
 
     Mean (SD) 
     Median (Min-Max) 
     IQR (Q1-Q3) 
 
(n = 25) 
 
11.6 (5.1) 
11.0 (3.0-23.0) 
(8.0-14.0) 
(n = 32) 
 
12.9 (7.4) 
11.0 (0-35.0) 
(8.0-17.0) 
 
 
0.663 
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Total MBQ Score (out of total 100 
possible) 
 
     Mean (SD) 
     Median (Min-Max) 
     IQR (Q1-Q3) 
 
(n=25) 
 
 
39.7 (13.4) 
36.9 (14.9-67.3) 
(33.0-46.2) 
(n=32) 
 
 
45.5 (15.2) 
42.2 (23.8-93.7) 
(34.9-50.2) 
 
 
 
0.143 
 
1Fisher’s exact test  
2T-test 
3Wilcoxon rank-sum 
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SF-36: Heavy/Regular Versus Heavy/Irregular 
Survey response data are presented in Table 5. 
Physical Functioning (PF) 
Women with heavy/regular bleeding had a mean score of 91.1 with a standard deviation 
of 16.7. The median score was 100 with a range of 40 to 100. The IQR was between 90 to 
100. 
Among women with heavy/irregular bleeding, they had a mean score of 78.6 with a 
standard deviation of 27.7. The median score was 95 with a range of 20 to 100. The IQR 
was between 50 to 100.  (p = 0.16) 
 
Role-Physical (RP) 
Women with heavy/regular bleeding had a mean score of 83.8 with a standard deviation 
of 21.5. The median score was 93.8 with a range of 31.3 to 100. The IQR was between 75 
to 100. 
Among women with heavy/irregular bleeding, they had a mean score of 72.1 with a 
standard deviation of 29.4. The median score was 87.5 with a range of 25 to 100. The 
IQR was between 50 to 100.  (p = 0.19) 
 
Bodily Pain (BP) 
Women with heavy/regular bleeding had a mean score of 69.8 with a standard deviation 
of 22.6. The median score was 74 with a range of 22 to 100. The IQR was between 54 to 
84. 
	68 
Among women with heavy/irregular bleeding, they had a mean score of 55.8 with a 
standard deviation of 23.7. The median score was 52 with a range of 0 to 100. The IQR 
was between 41 to 100.  (p = 0.03) 
 
General Health (GH) 
Women with heavy/regular bleeding had a mean score of 78.5 with a standard deviation 
of 13.1. The median score was 81 with a range of 40 to 97. The IQR was between 72 to 
87. 
Among women with heavy/irregular bleeding, they had a mean score of 66.7 with a 
standard deviation of 22.1. The median score was 56.3 with a range of 6.3 to 81.3. The 
IQR was between 43.8 to 68.8.  (p = 0.14) 
 
Vitality (VT) 
Women with heavy/regular bleeding had a mean score of 60.3 with a standard deviation 
of 15.7. The median score was 62.5 with a range of 25.0 to 81.3. The IQR was between 
53.1 to 71.9. 
Among women with heavy/irregular bleeding, they had a mean score of 52.1 with a 
standard deviation of 20.5. The median score was 56.3 with a range of 6.3 to 81.3. The 
IQR was between 43.8 to 68.8.  (p = 0.14) 
 
 
 
	69 
Social Functioning (SF) 
Women with heavy/regular bleeding had a mean score of 87.5 with a standard deviation 
of 17.3. The median score was 100 with a range of 37.5 to 100. The IQR was between 75 
to 100. 
Among women with heavy/irregular bleeding, they had a mean score of 70.0 with a 
standard deviation of 26.5. The median score was 75 with a range of 0 to 100. The IQR 
was between 50 to 100.  (p = 0.009) 
 
Role-Emotional (RE) 
Women with heavy/regular bleeding had a mean score of 89.4 with a standard deviation 
of 18.0. The median score was 100 with a range of 41.7 to 100. The IQR was between 
83.3 to 100. 
Among women with heavy/irregular bleeding, they had a mean score of 72.8 with a 
standard deviation of 26.9. The median score was 79.2 with a range of 25 to 100. The 
IQR was between 50 to 100.  (p = 0.009) 
 
Mental Health (MH) 
Women with heavy/regular bleeding had a mean score of 78.8 with a standard deviation 
of 15.6. The median score was 80 with a range of 35 to 100. The IQR was between 75 to 
90. 
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Among women with heavy/irregular bleeding, they had a mean score of 67.0 with a 
standard deviation of 19.5. The median score was 70 with a range of 20 to 100. The IQR 
was between 55 to 85.  (p = 0.02) 
 
Physical Component Score (PCS) 
Looking solely at the PCS among women with heavy/regular bleeding, the mean score 
for this component was 51.8 with a standard deviation of 7.6. The median score was 54.7 
with a range of 25.4 to 59.3. The IQR was between 50.4 to 55.9. 
Women with heavy/irregular bleeding had a mean score of 46.8 with a standard deviation 
of 9.7. The median score was 48.2 with a range of 24.7 to 61.7. The IQR was between 
40.6 to 53.9.  (p = 0.03) 
 
Mental Component Score (MCS) 
Women with heavy/regular bleeding had a mean MCS of 51.2 with a standard deviation 
of 9.1. The median score was 53.9 with a range of 26.3 to 60.8. The IQR was between 
48.5 to 57.2. 
Among women with heavy/irregular bleeding, they had a mean score of 44.0 with a 
standard deviation of 11.6. The median score was 47.3 with a range of 21.5 to 60.3. The 
IQR was between 33.9 to 53.7.  (p = 0.02) 
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Total SF-36 Score 
Considering the total score of the survey, women who reported heavy/regular bleeding 
had a mean SF-36 score of 78.9, with a standard deviation of 15.2. The median score for 
this group was 82.9, with a range of 40 to 100. The IQR was between 73.2 and 89.8. 
Among women reporting heavy/irregular bleeding the mean SF-36 score was 66.9, with a 
standard deviation of 19.9. The median score for this group was 70.5, with a range of 
26.0 to 95.9. The IQR was between 51.5 and 83.9.  (p = 0.02) 
 	  
	72 
Table 5. Domain and Total SF-36 Scores. 
Results were tabulated by taking the domain scores and total score of the survey for 
participants with complete data. 
N = 60 Pre-Op Bleeding Pattern  
Variable Heavy/Regular 
(n = 25) 
Heavy/Irregular 
(n = 35) 
p-value 
Physical Functioning (PF) 
     Mean (SD) 
     Median (Min-Max) 
     IQR (Q1-Q3) 
 
(n = 23) 
91.1 (16.7) 
100 (40-100) 
(90-100) 
(n = 35) 
78.6 (27.7) 
95 (20-100) 
(50-100) 
 
0.163 
Role-Physical (RP) 
     Mean (SD) 
     Median (Min-Max) 
     IQR (Q1-Q3) 
 
(n = 22) 
83.8 (21.5) 
93.8 (31.3-100) 
(75-100) 
(n = 35) 
72.1 (29.4) 
87.5 (25-100) 
(50-100) 
 
0.193 
Bodily Pain (BP) 
     Mean (SD) 
     Median (Min-Max) 
     IQR (Q1-Q3) 
 
(n = 22) 
69.8 (22.6) 
74 (22-100) 
(54-84) 
(n = 35) 
55.8 (23.7) 
52 (0-100) 
(41-100) 
 
0.032 
General Health (GH) 
     Mean (SD) 
     Median (Min-Max) 
     IQR (Q1-Q3) 
 
(n = 20) 
78.5 (13.1) 
81 (40-97) 
(72-87) 
(n = 34) 
66.7 (22.1) 
69.5 (15-100) 
(57-82) 
 
0.033 
Vitality (VT) 
     Mean (SD) 
     Median (Min-Max) 
     IQR (Q1-Q3) 
 
(n = 20) 
60.3 (15.7) 
62.5 (25.0-81.3) 
(53.1-71.9) 
(n = 35) 
52.1 (20.5) 
56.3 (6.3-81.3) 
(43.8-68.8) 
 
0.143 
Social Functioning (SF) 
     Mean (SD) 
     Median (Min-Max) 
     IQR (Q1-Q3) 
 
(n = 22) 
87.5 (17.3) 
100 (37.5-100) 
(75-100) 
(n = 35) 
70.0 (26.5) 
75 (0-100) 
(50-100) 
 
0.0093 
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Role-Emotional (RE) 
     Mean (SD) 
     Median (Min-Max) 
     IQR (Q1-Q3) 
 
(n = 22) 
89.4 (18.0) 
100 (41.7-100) 
(83.3-100) 
(n = 34) 
72.8 (26.9) 
79.2 (25-100) 
(50-100) 
 
0.0093 
Mental Health (MH) 
     Mean (SD) 
     Median (Min-Max) 
     IQR (Q1-Q3) 
 
(n = 20) 
78.8 (15.6) 
80 (35-100) 
(75-90) 
(n = 35) 
67.0 (19.5) 
70 (20-100) 
(55-85) 
 
0.023 
Physical Component Score (PCS) 
     Mean (SD) 
     Median (Min-Max) 
     IQR (Q1-Q3) 
 
(n = 20) 
51.8 (7.6) 
54.7 (25.4-59.3) 
(50.4-55.9) 
(n = 33) 
46.8 (9.7) 
48.2 (24.7-61.7) 
(40.6-53.9) 
 
0.033 
Mental Component Score (MCS) 
     Mean (SD) 
     Median (Min-Max) 
     IQR (Q1-Q3) 
 
(n = 20) 
51.2 (9.1) 
53.9 (26.3-60.8) 
(48.5-57.2) 
(n = 33) 
44.0 (11.6) 
47.3 (21.5-60.3) 
(33.9-53.7) 
 
0.023 
Total SF-36 Score (average of 8 
domains) 
     Mean (SD) 
     Median (Min-Max) 
     IQR (Q1-Q3) 
 
(n = 23) 
 
78.9 (15.2) 
82.9 (40-100) 
(73.2-89.8) 
(n = 35) 
 
66.9 (19.9) 
70.5 (26.0-95.9) 
(51.5-83.9) 
 
0.023 
 
2T-test 
3Wilcoxon rank-sum 
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DISCUSSION 
 The goal of this thesis was to conduct a prospective study which would capture a 
more comprehensive picture of women’s satisfaction and quality of life before and after 
endometrial ablation treatment. Furthermore, it was important to differentiate between 
women who exhibited heavy/regular bleeding and women who exhibited heavy/irregular 
bleeding to evaluate if there were differences in their quality of life, tolerance levels, 
satisfaction levels, and baseline health factors which could indicate success or failure in 
regard to endometrial ablation treatment.  
 One of the original goals of the study was to recruit patients before their surgery 
and follow them at 3 months, 6 months, and 1 year post-surgery. There were a total of 63 
participants enrolled in the study. One of the obstacles encountered during the course of 
the study was the rate of retention. The results (Table 1) show that at 3 months’ post-
surgery, 41% (n = 26) of participants continued taking part in the study. The retention 
rate at each subsequent follow-up diminished each time. As a result of this retention 
issue, data that were tabulated were based on the original baseline data. This is of 
particular concern because in order to have significant data, a good-sized population is 
required. A decrease in the number of participants each time means that the data cannot 
be truly reflective of the population overall. Due to this problem, the study was unable to 
gain insight as to whether the pre-operative bleeding pattern was indicative of outcomes 
relating to satisfaction, quality of life, and treatment failure at future dates. One of the 
reasons for diminished participation may be that during each subsequent visit, 
participants filled out two questionnaires, that required investment of their time. This 
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paperwork was mailed out and relied upon the patient providing up-to-date contact 
information and reaching out should there be a change in address. Furthermore, these 
questionnaires had to be mailed back to WIH, which required a trip to a mailbox or a 
postal office on the part of the participant. Future endeavors might try to incorporate the 
use of online surveys that provide convenience for the participants and might improve 
retention of present study subjects.  
 An important classifying criteria for the study was to compare women who self-
reported heavy/regular bleeding to women who self-reported heavy/irregular bleeding. 
An important reason for this comparison is that usually the cause of AUB has different 
etiologies in these women. Of the patients surveyed, 95.2% (n = 60) classified their 
bleeding as heavy (Table 2). From this group, 18.6% (n = 11) had been experiencing 
heavy periods for about 1-2 years, and 61% (n = 36) had been experiencing heavy periods 
for two or more years. Additionally, women were asked about regularity, with 60.3% (n = 
38) indicating that their periods were irregular in nature. Of these women, 29.7% (n = 11) 
had had irregular periods for about 1-2 years, whereas 37.8% (n = 14) had been 
experiencing irregularity for two or more years.  
These values highlight how not only women tend to accommodate their bleeding, 
but also how long they are willing to tolerate the interference of bleeding in their lives. 
The fact that a majority of women tended to have had symptoms present for one or more 
years may also be indicative of women opting to pursue other treatments before finally 
choosing surgical intervention. In fact, after separating women into two groups based on 
heavy bleeding regularity and irregularity, a similar percentage in each group had 
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pursued treatment in the last two years (Table 3). Among heavy/regular bleeding 
participants, 56% (n = 14) had tried some treatment in the last two years compared with 
55.9% (n = 19) in the heavy/irregular bleeding participants. Looking at specific 
treatments, women in both groups reported using the oral contraceptive pill at about the 
same rate of 36%.  
However, there were differences in other forms of treatment which may relate 
back to the different etiologies that cause heavy/regular versus heavy/irregular bleeding 
(Table 3). Of the women who exhibited heavy/regular bleeding, 15.4% (n = 2) had 
undergone dilation and curettage, 35.7% (n = 5) had opted for oral progestin daily for 21 
days/month, and 21.4% (n = 3) had chosen some other form of treatment. Although these 
women pursued some hormonal treatment, the higher rate of D&C among women with 
heavy/regular bleeding compared to women with heavy/irregular bleeding demonstrated 
how the heaviness of menstrual bleeding may have influenced their decision to pursue a 
surgical procedure which entailed scraping of the endometrium. Looking at 
heavy/irregular bleeding, 22.2% (n = 4) chose to take oral progestin daily for 10-14 
days/month, and 52.6% (n = 10) opted for the LNG-IUS. Overall, this group tended to 
have pursued prior hormonal treatment in an attempt to regulate timing and amount of 
flow.  
 The results of the Baseline Health Form highlighted differences between bleeding 
patterns, with more negative effects manifesting in women with heavy/irregular bleeding 
(Table 3). These women tended to have a higher rate of tubal sterilization of 50% (n = 
17) compared with 24% (n = 6) in women with heavy/regular bleeding (Table 3). 
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Although the mean BMI values for both groups were very close, women with 
heavy/irregular bleeding had a tendency to have a higher BMI value. When it came to 
race, although a majority of the women in each group identified as white, being 
Hispanic/Latino increased the tendency to have heavy/irregular bleeding to a rate of 
22.9% (n = 8) versus the 4.2% (n = 1) incidence in heavy/regular bleeding women. 
The MBQ was developed to deal specifically with abnormal uterine bleeding in 
women. It is disease-specific and focuses on evaluating different aspects of bleeding in 
relation to quality of life, irregularity, pain, and heaviness of bleeding. The questionnaire 
was designed to detect a difference in different bleeding patterns, leading to more 
significant data. Women with heavy/regular bleeding women had consistent bleeding per 
month, with 96% reporting their flow as heavy or very heavy compared to 78.3% of 
women with heavy/irregular bleeding (Table 4). The heaviness of the menstrual bleeding 
was of greater concern to women who experienced regular periods, but it also showed 
that irregularity may be a driving factor in why women seek surgical treatment.  
 Women with heavy/irregular bleeding experienced more pain with their periods 
and more variability in their period duration. Irregular bleeding was also a greater factor 
in their work situation, their preparedness with sanitary products, and their awareness of 
bathroom availability in planning activities. For women with irregular bleeding, a higher 
percentage of these women reported the inability to predict when their periods would 
start and end. These data are important because they show how heavy/irregular bleeding 
can limit a woman’s life. The fact that women cannot predict their period means that 
women must always be prepared to handle their bleeding. Heavy/irregular bleeding is a 
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burden because by the time women seek treatment, they have either tried dealing with the 
problem at home or used less invasive therapies to reduce symptoms. By the time they 
reach surgical intervention, women are looking for a solution that will either diminish 
symptoms or make them disappear entirely. The total MBQ score reported that women 
with heavy/irregular bleeding had higher mean scores (45.5 with a standard deviation of 
15.2), indicative of a more negative effect on quality of life, compared to the mean scores 
of women with heavy/regular bleeding (39.7 with a standard deviation of 13.4).   
The SF-36 has been a commonly used questionnaire and measure in past bleeding 
studies. Although the questionnaire has been validated and used, one drawback is its very 
limited scope when it comes to evaluating bleeding. This questionnaire focuses more on 
general physical and mental health aspects. The questions tend to be nonspecific in 
regards to bleeding. Looking at the total SF-36 score, women with heavy/regular bleeding 
tended to score higher overall in mean score (78.9 with a standard deviation of 15.2), 
median score (82.9 with a range between 40 to 100), and IQR (73.2 to 89.8) (Table 5). A 
higher SF-36 score is equivalent to a better health status. Women with heavy/irregular 
bleeding tended to have lower mean scores (66.9 with a standard deviation of 19.9), 
lower median scores (70.5 with a range between 26.0 to 95.9), and IQR (51.5 to 83.9). 
Looking solely at mean scores, the difference between bleeding patterns was 16 points. 
Based on total SF-36 score results, heavy/irregular bleeding creates a greater burden on 
general health compared to heavy/regular bleeding.  
Another criticism is that the total SF-36 score might not be as reflective of general 
health and may be better representative of an individual by focusing on the PCS and 
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MCS. When data was analyzed in this manner, the difference between the bleeding 
patterns of the women became much smaller, almost by about half. Looking at the PCS 
mean score that difference was 5 points. Looking at the MCS mean score the difference 
was 7.2 points. Women with heavy/regular bleeding still reported higher scores, and thus 
better general health, in both the PCS and MCS.  
Ultimately, even though future studies can continue to use this tool because there 
is no real standard by which to measure bleeding, it must be used with the full 
understanding that it only reports on a few aspects of health, well-being, and general 
quality of life. Even then, the total SF-36 score may not be as representative of general 
health and the use of the PCS and MCS should be encouraged as a data measure. In any 
case, other tools should be considered when evaluating bleeding patterns among women.  
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CONCLUSION 
Abnormal uterine bleeding (AUB) is a problem affecting a large number of 
women throughout their reproductive years. AUB can manifest itself as heavy menstrual 
bleeding (HMB) and can also be accompanied by irregular timing of the menstrual flow. 
These symptoms have a profound impact on women’s quality of life and serves as one of 
the main reasons they seek treatment. Typically, the first-line therapies are medical, but 
as a result of their variable and low efficacy in treating AUB and HMB, women often 
pursue further treatment. This treatment may be surgical and can include either 
hysterectomy or endometrial ablation. Hysterectomy is the definitive treatment for AUB 
and HMB because of the 100% rate of amenorrhea that results; however, hysterectomy is 
an invasive surgery which carries substantial risk. Endometrial ablations, though lacking 
the same success rate as hysterectomies, are less invasive and carry fewer risks.  
Similar proportions of women with bleeding patterns of heavy/regular and 
heavy/irregular seek treatment for their bleeding through an endometrial ablation. 
Usually, a majority of women have been suffering symptoms of their bleeding for a 
minimum of one year. More than one-half of the women in each group have tried other 
therapies prior to surgery. Women with heavy/regular bleeding tend to suffer more from 
the effects of the amount of flow, whereas women with heavy/irregular bleeding 
experience a more negative impact on their daily lives because of the unpredictability of 
the timing of their period. The SF-36, though commonly used in other bleeding studies, 
only marked a small difference between women with heavy/regular bleeding and women 
with heavy/irregular bleeding when looking at the PCS and MCS. The difference 
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between the SF-36 total score was much larger. Overall, the domain scores and total SF-
36 scores found women with heavy/irregular bleeding experienced a greater burden. The 
MBQ, which is specific for bleeding, differentiates between the bleeding patterns of 
women with heavy/regular and heavy/irregular periods, and displays a greater burden for 
women with heavy/irregular bleeding. Furthermore, the MBQ informs about specific 
aspects related to bleeding.  
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APPENDIX A: Consent Form 
Outcomes of Surgical Interventions for Abnormal Uterine Bleeding 
Consent Form 
 
Principal Investigator: Kristen A. Matteson, MD, MPH 
 
Section A: The nature, duration and purpose of study  
You are being asked to participate in a research study being conducted at Women and 
Infants Hospital. We are looking at the effects of surgical treatments for women with 
abnormal uterine bleeding.  
Section B: The means by which it is conducted  
Surgery is a common treatment for abnormal uterine bleeding. This study will assess 
the various outcomes of surgical intervention, including relief of abnormal bleeding 
and quality of life after surgery. For this study, you will be asked to complete a series 
of questionnaires at 4 different times: (1) Prior to your scheduled surgery, (2) Three 
months after surgery, (3) Six months after surgery, and (4) One year after surgery. 
This consent form also grants research staff permission to contact you for up to 5 years 
following the surgery, if necessary, and to review your medical record for up to 10 
years to see how well your surgery worked for you.  
Each set of questionnaires will take 10 to 20 minutes for you to complete. The 
questions are multiple choice and will ask you about your medical and surgical 
history, gynecologic and obstetric history, period symptoms, past treatments for your 
periods, and demographic characteristics about yourself. You may skip a question if it 
makes you feel uncomfortable. These questionnaires will not have your name on them 
and will be identified only by a study ID number. Information from the completed 
forms will be protected in a secure study database. At the time of consent, you will 
also complete a contact information form so that study staff can reach you during the 
study as necessary. You will be responsible for notifying study staff of any changes to 
this contact information throughout the study period.  
Section C: The possible benefit  
You will not receive any personal benefit from participating in this study. You will be  
helping researchers to better understand the various outcomes of surgical treatment for 
women with abnormal uterine bleeding.  
Section D: The potential risks and discomforts  
The only risk specific to participating in this study is that you may find some of the 
questions personal. If you wish to not answer specific questions or to discontinue a 
survey, you may do so. The research team will look at your medical records during the 
course of your treatment to collect information for research purposes only and make 
every effort to protect the privacy of your personal health information.  
Section E: Alternatives  
You do not have to participate in this study. If you decide not to participate, you will 
still receive standard care from your doctor. You can withdraw from this study at any 
time without any penalty.  
	83 
Project Title: Outcomes of Surgical Interventions for Abnormal Uterine Bleeding  
1. I have been told about this study. The procedures have been discussed with me. I 
have had a chance to ask questions. My questions were answered to my 
satisfaction.  
2. I authorize my confidential, protected health care information. My confidential 
health care information will be used only as necessary to participate in this study. 
Except when required by law, I will not be identified in study records disclosed 
outside this hospital by name, social security number, address, telephone number, 
or any other direct personal identifier. For records disclosed outside this Hospital, 
the investigator or her staff will assign me a unique identifying code. The key to 
the code will be kept in a password protected file.  
3. Information may have to be released when required by law when reasonable cause 
is shown under government regulations, or proper judicial orders. It may also be 
released to an official of the United States Food and Drug Administration, the 
United States Department of Health and Human Services, the United States 
Inspector General, the United States Office of Civil Rights, and representatives of 
Women & Infants’ Hospital and its Institutional Review Board. If my research 
record is reviewed by any of these groups, they may also need to review my entire 
medical record.  
4. I authorize the retention of the study results in my research record for at least ten 
years, or until after the study is completed, whichever is longer. At that time, 
either the research information which is not already in my medical record will be 
destroyed, or information identifying me will be removed from such study 
records. Any research information in my medical record will be kept indefinitely.  
5. Any information from the study will be used for education or research purposes. 
My name will not be used.  
6. I will be informed of any changes to the risks or benefits of this study.  
7. I do not have to take part in this study. I do not have to authorize use of my 
confidential, protected health information. My authorization to share my 
protected, personal health information expires two years after the study is 
completed.  
8. I am free to withdraw my consent at any time. I am free to stop taking part in the 
study at any time. I will still receive the best care possible. If I withdraw my 
consent or permission, the information that has already been collected about me 
by the researchers, will be kept by the researchers  
9. If I have questions about this study, I may call Dr. Matteson at (401) 274-1122 
extension 48562. If I have questions about my rights as a research subject, I may 
call the Director of IRB Administration at (401) 453-7677.  
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10. I can get the health information that was collected as part of this study. To do this, 
I may call Dr. Matteson at (401)274-1122 extension 48562 and she will give me 
information on how to send a written request. Once I send a written request for 
my health information, it will be sent to me as soon as a summary can be made.  
11. I will be given a copy of this consent form.  
 
Signature:_____________________________ Date:___________  
Name (please print):_____________________________________  
Name of Translator (if used):______________________________  
Translator’s signature:___________________________________  
Person who explained study:______________________________ Date:____________  
Hospital policy states that the signed original consent form is to be included in the 
subject’s medical record. One copy of the original signed consent form is to be given to 
the subject. One copy of the signed consent form should be retained in the investigator’s 
files.  
 
 
 
 
  
IRB NUMBER: 792602  
IRB APPROVAL DATE: June 6, 2016  
IRB EXPIRATION DATE: June 5, 2017  	 Version 1.1: 7/16/2014  	
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APPENDIX B: Locator Form 
Date:	____/____/__________	RA:	_________	
	 		 □Initial/Consent					□3	Month	 	□6	Month					□One	Year	
	
	 Outcomes	of	Surgical	Interventions	for	Abnormal	Uterine	Bleeding	
Locator	Form	
Thank	you	for	your	participation	in	our	research	study!	We	would	like	to	obtain	your	current	
contact	information	so	that	we	can	get	in	touch	with	you	for	your	future	study	visits.	At	your	
initial	visit	when	completing	this	form,	we	will	ask	for	your	ethnicity	and	race	for	reporting	
purposes	because	this	is	government	funded	research.		
	
We	ask	that	you	contact	us	if	any	of	the	information	provided	below	changes	or	you	no	longer	
wish	for	us	to	contact	you	by	using	the	information	that	you	have	provided.	If	you	give	us	
permission	to	contact	other	individuals	listed	below,	we	will	not	share	any	information	you	have	
disclosed	to	us.	We	only	ask	for	other	contacts	so	that	we	are	able	to	reach	you	for	future	study	
visits.	
First	Name:	________________Last	Name:	____________________			Birth	date:	___/___/____		Address:	_____________________________________________________________________	
City:	________________________________	State:	__________	Zip:	_____________________	
Cell:	____________________	Home:	___________________	Work:	______________________	
What	is	the	best	time	to	reach	you?	________________________________________________	
What	is	the	best	number	to	reach	you?				□	Cell			□	Home			□	Work				□	other	phone	__________			
May	we	leave	messages	at	this	number?	 □	Yes	 	□	No				 	
May	we	identify	the	study?	 □	Yes				 	□	No		 If	no,	we	will	say	we	are	calling				
																																																																																																																from	Women	and	Infants	Hospital			
	 May	we	contact	you	using	email?	 	 	 	 	
□	Yes				 Email	address:	__________________________@	_________________	
□	No	
	 May	we	send	you	text	messages	reminders?	 	 □	Yes				 	 □	No	
	 Which	language	do	you	prefer	to	use	for	study	visits?	 □	English					 □	Spanish	
	
Address:	______________________________________________________________________	
City:	__________________________________	State:	__________	Zip:	____________________	
 
Company:	_________________________________	Position:___________________________	
Address:	_____________________________________________________________________	
City:	_________________________________	State:	_________	Zip:	____________________	
Is	it	okay	to	contact	your	job	to	ask	how	we	can	contact	you?	 □Yes				 □	No	
 
 
Current	mailing	address	
Home	address	(if	different	than	mailing	address)	
Work/	Employment	
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First	name:	________________________	Last	name:	_________________________________	
She/he	is	my:		______________________	Best	time	to	call:	_____________________________	
Address:	______________________________________________________________________	
City:	_________________________________	State:	_________	Zip:_______________________	
Cell:	_____________________	Home:	_____________________	Work:	____________________	
	
First	name:	________________________	Last	name:	_________________________________	
She/he	is	my:		______________________	Best	time	to	call:	_____________________________	
Address:	______________________________________________________________________	
City:	_________________________________	State:	_________	Zip:	______________________	
Cell:	_____________________	Home:	_____________________	Work:	____________________	
	
First	name:	________________________	Last	name:	_________________________________	
She/he	is	my:		______________________	Best	time	to	call:	_____________________________	
Address:	______________________________________________________________________	
City:	_________________________________	State:	_________	Zip:	______________________	
Cell:	_____________________	Home:	_____________________	Work:	____________________	
 
Group	or	Office	Name:	________________________	Provider	Name:	_____________________	
Address:	______________________________________________________________________	
City:__________________________________	State:__________	Zip:_____________________	
Telephone	Number:	____________________________________________________________	
	 Is	it	okay	to	contact	this	provider	to	ask	how	we	can	contact	you?	 □Yes				 □	No	
 
By	signing	below,	I	give	permission	for	study	staff	to	contact	me	for	study	related	purposes.	I	
understand	that	no	study	information	will	be	given	to	anyone	other	than	myself	when	I	am	
contacted	to	schedule	or	confirm	a	follow-up	visit.	I	understand	that	I	can	contact	staff	if	I	no	
longer	desire	to	be	contacted.	I	also	understand	that	research	staff	will	ask	me	at	each	follow-
visit	to	update	this	information.	If	I	have	any	questions	or	wish	to	contact	staff	I	can	call	the	
numbers	that	have	been	provided.		
 
Signature:	_________________________________________________Date:	_______________		
	
Witness:	__________________________________________________Date:________________	
 
  
Family	Member/Friend	we	could	contact	to	get	in	touch	with	you	
Primary	Gynecologic	Care	Provider	
	87 
APPENDIX C: Baseline Health Form 	
Outcomes of Surgical Interventions for Abnormal Uterine Bleeding 	
	
Baseline	Health	Form		
	
This is a Research Assistant administered questionnaire. 
These questions ask for details about your medical problems, medications you may be taking, 
surgeries you have had, and your background.  For this questionnaire, “period” refers to any 
bleeding that you have from your vagina, even if it is irregular.  
 
 
Menstrual History 
 
1. Are your periods currently heavy? 
  0   No  (If NO, skip to question 3) 
  1   Yes   
 
2. How long have your periods been heavy? (Please choose one option) 
  1   Less than 3 months 
  2   From 3 months up to 6 months 
  3   From 6 months up to a year 
  4   From one year up to 2 years  
  5   Two years or greater 
  
3. Are your periods currently irregular? 
  0   No  (If NO, skip to question 5) 
  1   Yes   
 
4. How long have your periods been irregular? (Please choose one option) 
  1   Less than 3 months 
  2   From 3 months up to 6 months 
  3   From 6 months up to a year 
  4   From one year up to 2 years  
  5   Two years or greater 
 
Previous Care for Heavy/Irregular Menstrual Bleeding 
 
5. Many treatments can be used for heavy and/or irregular menstrual bleeding.  These 
can include medicines, injections, patches, rings, an intrauterine device, or surgical 
procedures. In the past two years, have you previously tried any treatments for your 
period? 
  0   No  (If NO, skip to question 16)  
  1   Yes  (If YES, continue) 
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6. Which of the following treatments for your period have you tried in the past two 
years?  Check all that apply. Read each option to the patient.  
 
 
Treatment Did you use this treatment in the past six months?  
□1  Oral contraceptive pills (birth control pill) □0No  □1Yes  □8Don’t know   
□2  Contraceptive patch (OrthoEvra) □0No  □1Yes  □8Don’t know   
□3  NuvaRing □0No  □1Yes  □8Don’t know   
□4  Danazol □0No  □1Yes  □8Don’t know   
□5  GnRH agonist (Lupron) □0No  □1Yes  □8Don’t know   
□6  Non-steroidal Anti-Inflammatory Drug 
(Ibuprofen: Advil, Motrin) □0No  □1Yes  □8Don’t know   
□7  Oral progestin daily for 10-14 days/ month 
(Provera or Aygestin) □0No  □1Yes  □8Don’t know  
□9  Oral progestin daily for 21 days/ month 
(Provera or Aygestin) □0No  □1Yes  □8Don’t know  
□10  Depo- Provera injection □0No  □1Yes  □8Don’t know   
□11  Levonorgestrel Intrauterine System (Mirena) □0No  □1Yes  □8Don’t know   
□12  Dilation and Curettage □0No  □1Yes  □8Don’t know   
□8 Other:_____________________   
 
 
Obstetric History 
 
The next few questions I will ask you are about pregnancy. 
 
7. In total, how many times have you been pregnant: _____ 
  0   None  (If NONE, skip to question 20) 
 
8. In total, how many of these pregnancies resulted in deliveries: _____ 
 
9. Were any of these deliveries caesarean deliveries (C-section)? 
  0  No   
  1  Yes   If yes, how many? _____ 
 
10. Have you had any miscarriages, abortions, or ectopic pregnancies (pregnancies 
outside your uterus, typically in your fallopian tubes)? 
  0  No   
  1  Yes    If yes, how many? _____ 
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Gynecologic & Surgical History 
The next several questions are about your past medical problems, procedures you might 
have had, and surgeries. 
 
11. Have you ever been told by a healthcare provider that you have endometrial 
hyperplasia (abnormal thickening of the lining of the uterus)? 
  0  No  
  1  Yes  
  8  I don’t know 
 
12. Endometrial sampling  
a. Have you ever had an endometrial biopsy? 
  0  No  (If NO, skip to question 23.b) 
  1  Yes (If YES, continue) 
  8  Don’t know  (If Don’t know, skip to question 23.b) 
 
What was the date of most your most recent endometrial biopsy: 
 
 ___ ___ / ___ ___ / ___ ___ ___ ___ 
     Mo          Day              Year 
 
If parts of date unknown, insert “9”.  For example, May 2011 would be 05/99/2011 
 
b. Have you ever had a dilation and curettage (D&C) unrelated to a 
pregnancy? 
 
  0  No (If NO, skip to question 24) 
  1  Yes  (If YES, continue) 
  8  Don’t know  (If Don’t know, skip to question 24) 
 
  
Date of most recent D&C: ___ ___ / ___ ___ / ___ ___ ___ ___ 
                            Mo          Day              Year 
 
13. Polyps 
a. Have you ever had an endometrial polyp?  
  0  No  (If NO, skip to question   ) 
  1  Yes  (If YES, continue) 
 
b. Have you ever had an endometrial polyp removed?  
  0  No  (If NO, skip to question 26) 
  1  Yes  (If YES, continue) 
 
c. Date of most recent polyp removal: ___ ___ /___ ___ /___ ___ ___ ___ 
                                                      Mo           Day            Year 
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14. Have you ever had any of the following surgical procedures? 
 
               
 No Yes Don’t know 
a. Tubal sterilization (tubes tied or blocked using 
Essure) □0 □1 □8 
b. Surgery for ovarian cyst □0 □1 □8 
c. Unilateral oophorectomy (removal of one ovary) □0 □1 □8 
d. Other pelvic surgery                                                                      □0                □1                          □8 
Specify: 
 
Demographic Information 
Now I am going to ask for some details about you. 
 
15. What is your current height in feet/inches?  ___ft.  ___ ___ inches 
  8 I don’t know 
 
16. What is your current weight in pounds?  ___ ___ ___ lbs. 
  8 I don’t know 
 
17. What is your ethnicity? 
  1   Hispanic or Latino 
  2   Not Hispanic or Latino 
  8   I do not know 
  98  I do not want to answer 
 
18. What is your race? 
  1   American Indian or Alaska Native 
  2   Asian 
  3   Black or African American 
  4   Native Hawaiian or Other Pacific Islander 
  5   White 
  8   I do not know 
  98  I do not want to answer 
 
19. Which of the following languages do you speak the MOST at home? Please select all 
that apply. 
  1   English 
  2   Spanish 
  3   Portuguese 
  4   French 
  5   Chinese 
  8   Other__________________________________________ 
  98  I do not want to answer 
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20. What is your current marital status? Please choose the one that best describes your 
status. 
  1   Married 
  2   Living with partner 
  3   Never Married 
  4   Widowed 
  5   Divorced or separated 
  98  I do not want to answer 
 
21. What is your current employment situation? Please select all that apply. 
  1   Working now Full Time  
  2   Working now Part Time  
  3   Temporarily Laid off 
  4   On maternity leave 
  5   On illness/sick leave 
  6   Unemployed  
  7   Retired  
  9   Full Time Homemaker 
  10  Student 
  11  Permanently Disabled 
  8   Other (Please 
Describe):______________________________________________ 
  98  I do not want to answer 
 
22. What is the highest grade of school you have completed? 
  1   0 to 6th grade 
  2   7th to 8th grade 
  3   9th to 11th grade 
  4   12th grade (completed high school) 
  5    Technical or trade school 
  6   Some college 
  7   Completed 4 year college  
  8   Graduate or professional school 
  98  I do not want to answer 
 
 
 
FOR HEALTHCARE PROVIDER: 
23.  Etiology of patient’s abnormal uterine bleeding: 
  1  AUB-P 
  2  AUB-A 
  3  AUB-L 
  4  AUB-M 
  5   AUB-C 
  6  AUB-O 
  7  AUB-E 
  8  AUB-I 
  9  AUB-N 
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APPENDIX D: Short Form-36 Health Survey 
 
 
Your Health and Well-Being
 
 
This survey asks for your views about your health. This information will help 
keep track of how you feel and how well you are able to do your usual activities. 
Thank you for completing this survey! 
 
For each of the following questions, please mark an  in the one box that best 
describes your answer. 
 
1. In general, would you say your health is: 
 
Excellent Very Good Good Fair Poor 
▼ ▼ ▼ ▼ ▼ 
	1 	2 	3 	4 	5 
 
 
 
2. Compared to one year ago, how would you rate your health in general now? 
 
Much better 
now than one 
year ago 
Somewhat 
better 
now than one 
year ago 
About the 
same as 
one year ago 
Somewhat 
worse 
now than one 
year ago 
Much worse 
now than one 
year ago 
▼ ▼ ▼ ▼ ▼ 
	1 	2 	3 	4 	5 
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3. The following questions are about activities you might do during a typical day. 
Does your health now limit you in these activities? If so, how much? 
 
 
  Yes, 
limited a 
lot 
Yes, 
limited a 
little 
No, not 
limited at 
all 
  ▼ ▼ ▼ 
a Vigorous activities, such as running, 
lifting heavy objects, participating in 
strenuous sports 
	1 	2 	3 
b Moderate activities, such as moving a 
table, pushing a vacuum cleaner, 
bowling, or playing golf 
	1 	2 	3
c Lifting or carrying groceries 	1 	2 	3
d Climbing several flights of stairs 	1 	2 	3
e Climbing one flight of stairs 	1 	2 	3
f Bending, kneeling, or stooping 	1 	2 	3
g Walking more than a mile 	1 	2 	3
h Walking several hundred yards 	1 	2 	3
i Walking one hundred yards 	1 	2 	3
j Bathing or dressing yourself 	1 	2 	3
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4. During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of your 
physical health? 
 
  All of 
the 
time 
Most 
of 
the 
time 
Some 
of 
the 
time 
A 
little 
of 
the 
time 
None 
of 
the 
time 
  ▼ ▼ ▼ ▼ ▼ 
a Cut down on the amount of 
time you spent on work or 
other activities 
	1 	2 	3 	4 	5 
b Accomplished less than you 
would like 	1 	2 	3 	4 	5
c Were limited in the kind of 
work or other activities 	1 	2 	3 	4 	5
d Had difficulty performing the 
work or other activities (for 
example, it took extra effort) 
	1 	2 	3 	4 	5
 
5. During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of any 
emotional problems (such as feeling depressed or anxious)? 
 
  All of 
the 
time 
Most 
of 
the 
time 
Some 
of 
the 
time 
A 
little 
of 
the 
time 
None 
of 
the 
time 
  ▼ ▼ ▼ ▼ ▼ 
a Cut down on the amount of 
time you spent on work or 
other activities 
	1 	2 	3 	4 	5 
b Accomplished less than you 
would like 	1 	2 	3 	4 	5
c Did work or other activities 
less carefully than usual 	1 	2 	3 	4 	5
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6. During the past 4 weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, 
neighbors, or groups? 
 
Not at all Slightly Moderately Quite a bit Extremely 
▼ ▼ ▼ ▼ ▼ 
	1 	2 	3 	4 	5 
 
 
7. How much bodily pain have you had during the past 4 weeks? 
 
None Very mild Mild Moderate Severe Very 
severe 
▼ ▼ ▼ ▼ ▼ ▼ 
	1 	2 	3 	4 	5 	6
 
 
 
8. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)? 
 
Not at all A little bit Moderately Quite a bit Extremely 
▼ ▼ ▼ ▼ ▼ 
	1 	2 	3 	4 	5 
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9. These questions are about how you feel and how things have been with you 
during the past 4 weeks. For each question, please give the one answer that comes 
closest to the way you have been feeling. How much of the time during the past 4 
weeks… 
 
  All of 
the 
time 
Most of 
the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
  ▼ ▼ ▼ ▼ ▼ 
a Did you feel full of life? 	1 	2 	3 	4 	5
b Have you been very nervous? 	1 	2 	3 	4 	5
c Have you felt so down in the 
dumps that nothing could 
cheer you up? 
	1 	2 	3 	4 	5
d Have you felt calm and 
peaceful? 
	1 	2 	3 	4 	5
e Did you have a lot of energy? 	1 	2 	3 	4 	5
f Have you felt downhearted 
and depressed? 
	1 	2 	3 	4 	5
g Did you feel worn out? 	1 	2 	3 	4 	5
h Have you been happy? 	1 	2 	3 	4 	5
i Did you feel tired? 	1 	2 	3 	4 	5
 
 
10. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with 
friends, relatives, etc.)? 
 
All of the 
time 
Most of the 
time 
Some of the 
time 
A little of the 
time 
None of the 
time 
▼ ▼ ▼ ▼ ▼ 
	1 	2 	3 	4 	5 					
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11. How TRUE or FALSE is each of the following statements for you? 
 
  Definitely 
true 
Mostly 
true 
Don’t 
know 
Mostly 
false 
Definitely 
false 
  ▼ ▼ ▼ ▼ ▼ 
a I seem to get sick a 
little easier than 
other people 
 
	1 	2 	3 	4 	5
b I am as healthy as 
anybody I know 
 
	1 	2 	3 	4 	5
c I expect my health 
to get worse 
 
	1 	2 	3 	4 	5
d My health is 
excellent 
	1 	2 	3 	4 	5
 
 
Thank you for completing these questions! 	  
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APPENDIX E: Menstrual Bleeding Questionnaire 
Menstrual Bleeding Questionnaire 
 
These questions ask for details about your period. Periods can be different from month to month. 
Please make sure you read all of the options. For this questionnaire, period refers to any bleeding 
that you have from your vagina, even if it is irregular.   
 
Some of the questions may sound similar. Just read through each question carefully and give 
your best answer. 
 
You may have other medical problems that could affect your answers. Please try to focus on 
questions and answers ONLY as they relate to your period. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. During the past month, how would you describe your periods?  
 
Very Light ................................................................................................................ [   ] 
Moderate ................................................................................................................. [   ] 
Heavy ...................................................................................................................... [   ] 
Very Heavy .............................................................................................................. [   ] 
Instructions for questions 2, 3, and 4.  
“High absorbency” sanitary products mean any type of tampon or a pad that is NOT a thin 
pantyliner. 
“Soaked” means completely or almost completely stained and filled with blood. 
 
 
 
 
 
During the past month, did you have ANY bleeding? 	
Yes…………………………………………………………………… [   ] 
 
No………………………………………………………………….…. [   ]		
If you answered “YES” continue to question 1. 
If you answered “NO” skip to question 12.  
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2. On your heaviest day of bleeding during the past month, how many high 
absorbency   sanitary products did you soak (either completely or almost 
completely)?  
0 ............................................................................................................................... [   ] 
1-4 ........................................................................................................................... [   ] 
5-8 ........................................................................................................................... [   ] 
9-12 ......................................................................................................................... [   ] 
13-16 ....................................................................................................................... [   ] 
More than 16 ........................................................................................................... [   ] 
 
3. During the past month, how often did you need to wear either an incontinence 
brief or more than one high absorbency sanitary product (either more than one 
pad, a pad and a tampon, more than one tampon) at a time to contain your 
bleeding? 
Never ....................................................................................................................... [   ] 
1-3 times .................................................................................................................. [   ] 
4-6 times .................................................................................................................. [   ] 
7-10 times ................................................................................................................ [   ] 
11 times or greater .................................................................................................. [   ] 
4. During the past month, how many times have you had an episode of bleeding 
that soaked through your “outer” clothes (pants, skirt, dress)? 
Never ....................................................................................................................... [   ] 
1-3 times .................................................................................................................. [   ] 
4-6 times .................................................................................................................. [   ] 
7-10 times ................................................................................................................ [   ] 
Greater than 6 times ................................................................................................ [   ] 
5. During the past month, how many times did you need to get out of bed in the 
middle of night (or during sleep hours) to change your sanitary products? 
Never ....................................................................................................................... [   ] 
1-3 times .................................................................................................................. [   ] 
4-6 times .................................................................................................................. [   ] 
7-10 times ................................................................................................................ [   ] 
11 times or greater .................................................................................................. [   ] 
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6. During the past month, how many times did you pass blood clots (clumps of 
blood)? 
Never ....................................................................................................................... [   ] 
1-3 times .................................................................................................................. [   ] 
4-6 times .................................................................................................................. [   ] 
7-10 times ................................................................................................................ [   ] 
Greater than 6 times ................................................................................................ [   ] 
7. During the past month, how often did passing blood clots (clumps of blood) 
stain your clothing? 
Never ....................................................................................................................... [   ] 
1-3 times .................................................................................................................. [   ] 
4-6 times .................................................................................................................. [   ] 
7-10 times ................................................................................................................ [   ] 
Greater than 6 times ................................................................................................ [   ] 
8.  Please fill in the following statement about pain related to your period.  During 
the past month, my period was associated with…  
No pain .................................................................................................................... [   ] 
Slight pain ................................................................................................................ [   ] 
Moderate pain .......................................................................................................... [   ] 
Severe pain ............................................................................................................. [   ] 
9. During the past month, how many weeks did your periods last? 
1 week or less of of 4 weeks ................................................................................... [   ] 
More than 1 week, less than 2 weeks out of 4 weeks ............................................. [   ] 
More than 2 weeks, less than 3 weeks out of 4 weeks ........................................... [   ] 
More than 3 weeks out of 4 weeks .......................................................................... [   ] 
10. During the past month, on how many days do you think your work at your job 
suffered because you were bleeding?  
I am currently not working outside of the home ....................................................... [   ] 
Never, my bleeding does not affect my work ........................................................... [   ] 
1-3 days ................................................................................................................... [   ] 
4-8 days ................................................................................................................... [   ] 
9-12 days ................................................................................................................. [   ] 
13 days or more ....................................................................................................... [   ] 
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11. During the past month, on how many days did you miss work because you 
were bleeding? 
I am currently not working outside of the home ....................................................... [   ] 
Never, my bleeding does not affect my work ........................................................... [   ] 
1-3 days ................................................................................................................... [   ] 
4-8 days ................................................................................................................... [   ] 
9-12 days ................................................................................................................. [   ] 
13 days or more ....................................................................................................... [   ] 
12. During the past month, on how many days did you avoid family activities 
(grocery shopping, household chores) when you thought you would be bleeding? 
Never ....................................................................................................................... [   ] 
1-3 days ................................................................................................................... [   ] 
4-8 days ................................................................................................................... [   ] 
9-12 days ................................................................................................................. [   ] 
13 days or more ....................................................................................................... [   ] 
 
13. During the past month, when would you carry sanitary products (pads, 
tampons) with you (in your pocket, in your bag)? 
Every day, in case I had any bleeding ..................................................................... [   ] 
On the days when I had bleeding and on days when I guessed that I might have 
bleeding ................................................................................................................... [   ] 
Only on the days that I had bleeding ....................................................................... [   ] 
 
14. During the past month, on how many days did you avoid social activities (such 
as getting together with friends, going shopping for fun, going sight-seeing) when 
you thought you would be bleeding? 
 Never ...................................................................................................................... [   ] 
1-3 days ................................................................................................................... [   ] 
4-8 days ................................................................................................................... [   ] 
9-12 days ................................................................................................................. [   ] 
13 days or more ....................................................................................................... [   ] 
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15. During the past month, on how many days did you plan your activities (work, 
social, or family) based on whether or not there was a bathroom nearby? 
Never ....................................................................................................................... [   ] 
1-3 days ................................................................................................................... [   ] 
4-8 days ................................................................................................................... [   ] 
9-12 days ................................................................................................................. [   ] 
13 days or more ....................................................................................................... [   ] 
16. During the past month, on how many days did you bring extra clothes with you 
(to work, out shopping) in case you had staining from your period? 
Never ....................................................................................................................... [   ] 
1-3 days ................................................................................................................... [   ] 
4-6 days ................................................................................................................... [   ] 
Greater than 6 days ................................................................................................. [   ] 
17. During the past month, on how many days did you choose what to wear based 
on whether or not you were bleeding? 
Never ....................................................................................................................... [   ] 
1-3 days ................................................................................................................... [   ] 
4-8 days ................................................................................................................... [   ] 
9-12 days ................................................................................................................. [   ] 
13 days or more ....................................................................................................... [   ] 
18. On a scale of 0-10, with 0 being no concern at all and 10 being extremely 
concerned, please rate your overall concern about bleeding staining your clothes. 
_______________   
 
19. During the past month, would you say that your period start date was… 
Completely predictable ............................................................................................ [   ] 
Somewhat predictable ............................................................................................. [   ] 
Not at all predictable ................................................................................................ [   ] 
20. During the past month, would you say that your period end date was… 
Completely predictable ............................................................................................ [   ] 
Somewhat predictable ............................................................................................. [   ] 
Not at all predictable ................................................................................................ [   ] 
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